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Nucleotide excision repair (NER) is responsible for the repair of a wide range of DNA 
lesions, including UV-induced photoproducts and bulky base adducts. XPA is an essential protein 
in eukaryotic NER, although questions about its stoichiometry and mechanism of damage 
recognition have been heretofore unresolved. Regions of intrinsic disorder within the N- and C-
termini of XPA have made structural work on the full-length protein challenging and compel an 
alternative approach. We have used PeakForce Tapping® atomic force microscopy to show that 
human XPA binds to DNA as a monomer and bends it ~60°. Furthermore, XPA demonstrated 
specificity for the helix-distorting base adduct, N-(2’-deoxyguanosin-8-yl)-2-
acetylaminofluorene. Single molecule fluorescence microscopy revealed that DNA-bound XPA 
exhibits multiple modes of linear diffusion between paused phases. These included long distance 
motion with rapid diffusion (D ≈ 0.04 μm2/s) consistent with hopping and short distance motion 
(D ≈ 0.0003 μm2/s) consistent with sliding along the DNA contour. The presence of DNA damage 
increases pausing by proteins undergoing one-dimensional target search. A truncated mutant, 
lacking most of the intrinsically disordered regions and made up of just residues 98-239 of the 
DNA binding domain, exhibits less pausing on UV-damaged DNA compared to the full length 
protein. In summary, our data are consistent with a model in which the conformational state of 
XPA is dependent upon the presence of DNA damage and bending. 
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1.0 Introduction 
1.1 Protein Target Search on DNA 
In order for any DNA-binding protein to function, it must find its target. This is true for 
proteins like transcription factors and restriction enzymes that bind specific DNA sequences as 
well as DNA repair proteins that bind to specific forms of base damage. In a human cell, which 
contains a high ratio of non-specific/specific DNA binding sites, this can be seen as the biological 
equivalent of searching for a needle in a haystack of 109 base pairs. 
Early work by von Hippel and colleagues have laid the foundation for subsequent studies 
on protein-DNA target search. An important series of their papers laid out theoretical calculations 
relating to diffusion and applied them to lac repressor, a bacterial protein which regulates gene 
expression by binding to the lac operon sequence in DNA1-4. Free proteins in solution undergo 
Brownian motion and must rely on random collision with the appropriate site to find their target. 
Furthermore, the properties required for recognition drop off significantly if the protein binds even 
one base pair (0.34 nm) away from the target5. Still, three-dimensional diffusion may be an 
effective method if protein concentrations are sufficiently high, thereby increasing the probability 
of a specific collision6. However, many DNA-binding proteins are expressed at relatively low 
levels. For example, E. coli cells only contain about ten copies of the lac repressor7. Similarly, one 
HeLa cell contains between 2.5 and 8 × 104 molecules of XPC, a protein involved in damage 
recognition during nucleotide excision repair8,9; this is several orders of magnitude less than the 
number of possible non-specific binding sites. In cases like these, a three-dimensional search may 
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actually take longer than a one-dimensional searchi. By reducing target search to just one 
dimension, a relatively low copy number of search proteins can find their target more efficiently 
than via a purely three-dimensional process10,11. 
Biological evidence for this type of search strategy was first reported for the lac repressor, 
which is able to find the lac operon sequence faster than theoretically possible for a three-
dimensional search11. Consequently, this process has been deemed facilitated diffusion1,2,4. Four 
major categories of facilitated diffusion have been defined: sliding, hopping (microscopic 
dissociation-reassociation events), jumping (macroscopic dissociation-reassociation events), and 
intersegmental transfer between segments within the same DNA molecule1. Typically, it is 
understood that the protein will bind DNA at any site, due to some affinity for non-specific DNA, 
and then transition from a three-dimensional to a one-dimensional search, undergoing some 
combination of one or more facilitated diffusion processes. This two-step reaction scheme has 
been suggested by early theoretical work for molecular interactions in general10,12, and protein-
DNA binding in particular1. 
Later work by Slutsky, Mirny, and others, have investigated the role of protein-DNA 
energy binding landscapes in recognition of and binding to specific DNA sites. A protein 
undergoing a random walk during linear diffusion encounters a wide variety of energy potentials 
for DNA-binding13. Slutsky and Mirny proposed a model in which proteins must diffuse rapidly 
along vast sequences of DNA in order to adequately sample the DNA. This type of diffusion 
requires a relatively smooth binding energy landscape and that proteins are interacting with DNA 
 
i Please refer to Section 2.6.5 for further discussion of the limits of one-dimensional diffusion, in the context 
of a protein translocating along DNA in vitro. 
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relatively loosely. The authors conclude such a mechanism dictates that proteins encounter and 
overcome relatively small free energy barriers, less than 1–2 × kBT (where kBT is the thermal 
energy term: the product of the Boltzmann constant, kB, and temperature, T, or ~4.11 × 10
-21 J at 
25°C)5,14. The smooth energy landscape prevents the protein from getting trapped in any one 
position and allows for acceleration of target search. However, the interactions required to 
recognize a target site and form a stable protein-DNA complex require an energy landscape rugged 
enough to inhibit protein diffusion. This can only be achieved with free energy barriers greater 
than 5 × kBT (refs. 
5,14). This concept has been named the search-speed/stability paradox, as these 
two states have mutually exclusive energy requirements5. To reconcile these conflicting 
requirements for target site recognition, Slutsky and Mirny proposed a two-state model, whereby 
the protein can adopt two conformations5,14. The “search state” corresponds to a structural 
conformation allowing for fast linear diffusion and smooth energy landscapes with standard 
deviation σ ≲ 1–2 × kBT. The “recognition state” corresponds to a rugged energy landscape, σ ≳ 
5 × kBT, and higher affinity complexes. Hu and Shklovskii also report that energetic disorder, 
leading to rugged energy landscapes, slows linear diffusion of proteins bound to DNA15. 
Single molecule studies by van Oijen and colleagues provide compelling evidence that the 
transcription factor p53 adopts these two conformations (i.e. a search state and a recognition state) 
during search for its cognate sequence16,17. The authors calculated diffusion constants from single 
particle tracking data and used this to predict and interpret corresponding energy landscapes. Their 
results indicate that p53 switches between two conformations: a search state with major contacts 
between C-terminal domains and DNA, and a recognition state where the core domains fold in, 
providing additional contacts with the DNA and resulting in slower diffusion16. These principles 
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have also been studied for DNA repair proteins, including Msh2-Msh618, thymine DNA 
glycosylase19, MutS20, UV-DDB21, Rad422, and PARP123. 
1.2 Nucleotide Excision Repair 
Our genomes are subject to constant assault and suffer approximately 10,000 to 70,000 
lesions per cell per day24. Nucleotide excision repair (NER) is a highly conserved DNA repair 
pathway that is able to specifically recognize and repair a wide range of structurally and chemically 
distinct DNA lesions. In humans, this process involves approximately 30 proteins, working 
together to protect our genomes from the damaging effects of UV radiation and chemical 
carcinogens. 
1.2.1  DNA Lesions Repaired by NER 
Though diverse, the majority of lesions repaired via the NER pathway destabilize or distort 
the DNA helix in some way. UV radiation (254 nm) causes formation of two major lesions in 
DNA: the cyclobutane pyrimidine dimer (CPD) and 6-4 photoproduct (6-4PP), at a ratio of 
approximately three to one25,26. NMR studies have shown that 6-4PP lesions cause significant 
bending (44°) in the DNA helix and disrupt hydrogen bonding; in contrast, DNA with a CPD 
lesion maintains a B-form helix with a 9° bend27. Cisplatin, commonly used in cancer 
chemotherapy, readily forms covalent attachments to purines in DNA, resulting in intrastrand 
crosslinks, interstrand crosslinks, and monoadducts28. The coordination complex containing 
cisplatin may be reversible with a strong reductant, such as cyanide. These adducts, and other 
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platinum derivatives, can be repaired via NER29. Furthermore, a diverse group of polycyclic 
aromatic hydrocarbons and aromatic amines are also recognized and repaired by NER. 
Acetylaminofluorene (AAF), a synthetic carcinogen which produces lesions at the C8 position of 
guanine, is one such well-studied substrate30-33. 
1.2.2  Steps in Eukaryotic NER 
The general steps of eukaryotic NER are illustrated in Figure 1. Like all DNA repair 
pathways, NER begins with a damage detection step. The NER damage detection step can be 
initiated in two general ways: during transcription or in chromatin34-36. During transcription-
coupled (TC) NER, RNA polymerase stalls at a site of damage and is recognized by Cockayne 
syndrome protein A (CSA) and Cockayne syndrome protein B (CSB), which promote removal of 
the polymerase from the damage site and recruitment of subsequent repair proteins. Recently, 
broader roles for CSA and CSB in proteasome-mediated degradation of an immediate early gene 
product and transcription restart after UV have been reported37. 
Global genome (GG) NER is initiated by UV-damaged DNA binding protein (UV-DDB) 
and/or XPC-RAD23B-CETN2 when they recognize the lesion at any site in the chromatin. UV-
DDB, a major sensor of UV photoproducts during GG NER, exists as a heterodimer of subunits 
DDB1 and DDB2. It is associated with the CUL4A-RBX E3 ubiquitin ligase which modifies core 
histones in response to UV radiation38-40. Single molecule analysis of the dynamics of UV-DDB 
binding to damaged DNA have indicated a conformational proofreading mechanism, where 
binding of UV-DDB at a site of DNA damage induces a conformational change in the protein 
which stabilizes the UV-DDB-lesion complex21. Rad4-Rad23 (yeast homolog of XPC-RAD23B) 
has been shown to exhibit anomalous subdiffusion during recognition of CPD lesions in DNA22. 
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This “recognition at a distance” allows for the assembly of subsequent repair events without steric 
interference. As discussed in the previous section, the NER recognition proteins appear to have 
specificity for DNA with disrupted base pairing or a thermodynamically destabilized helix, even 
in the absence of a traditional lesion36,41,42. 
The two NER pathways converge for a damage verification step, where the TFIIH helicase 
complex unwinds the DNA and tests for the presence of damage. The seven core subunits of TFIIH 
are essential for both transcription and NER: XPB, XPD, p62, p52, p44, p34, and p8/TTDA43. An 
additional CDK-activating kinase domain is required for transcription, but not for NER. 
Replication protein A (RPA) binds non-damaged single stranded DNA, stabilizing the pre-incision 
complex. After damage verification, endonucleases XPF-ERCC1 and XPG make sequential 
incisions, 5’ and 3’ of the lesion respectively. After incision by XPF-ERCC1, and before the XPG 
nuclease is activated, DNA polymerase (δ, ε, or κ) and PCNA assemble to begin DNA synthesis 
to fill in the gap. Then incision by XPG releases the lesion-containing 24-32 base 
oligonucleotide44,45. Finally, the new DNA backbone is sealed by DNA ligase (I or III)36. 
The protein XPA, discussed in depth in subsequent sections, is an essential protein in both 
TC and GG NER. It has no known enzymatic function. Initial reports on the function of XPA in 
NER conclude that it is involved in early steps of damage recognition46, although more recent 
models place XPA later in the pathway47, acting as a scaffold and interacting with other NER 
proteins48-54, and RPA in particular55-57. Though indispensable, the precise role of XPA during 
NER remains unclear, and likely is dependent on multiple factors, including type of damage and 
presence/absence of other factors. Importantly, it has been suggested that damage recognition in 
NER, which needs to be highly specific to a diverse range of structures, is accomplished via a 
“discrimination cascade” involving multiple proteins, each with imperfect selectivity58-60. In 
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support of this model, XPA enhances the damage specificity of TFIIH by promoting both its 
translocation along non-damaged DNA and stalling at a lesion61,62. As such, it remains of 
significant interest to investigate how XPA interacts with DNA lesions. 
1.2.3  Diseases Associated with NER 
Genetic mutations affecting NER proteins can cause multiple autosomal recessive 
disorders, reviewed in ref.63. These diseases are rare but come with significant challenges and 
decreased life expectancies. One major genetic disorder associated with defective NER is 
xeroderma pigmentosum (XP). There are seven types of XP, defined by complementation groups 
and named for the specific gene carrying the mutation: XPA, ERCC3 (XPB), XPC, ERCC2 (XPD), 
DDB2 (XPE), ERCC4 (XPF), and ERCC5 (XPG). An eighth type of XP, named XP variant (XPV), 
is caused by mutations in the gene coding for DNA polymerase η, involved in translesion DNA 
synthesis and not NER. XP patients suffer from extreme photosensitivity and develop skin cancer 
at an approximately 2,000-fold increased frequency over non-XP patients. While all XP types 
share similar clinical phenotypes, particularly with respect to UV sensitivity and skin cancer, there 
is some disparity among groups. XPA patients experience some of the most severe symptoms of 
the disease. Neurodegeneration is also prevalent among XPA, XPB, XPD, and XPG patients. XPB 
and XPD patients are also at risk for the related disorders Cockayne syndrome (CS) and 
trichothiodystrophy (TTD)63,64. 
CS patients do not develop cancers at the extreme rates of XP patients. CS is primarily 
associated with premature aging, neurodegeneration, and UV sensitivity64. The disorder is 
primarily caused by mutations in ERCC8 (encoding CSA protein) or ERCC6 (encoding CSB 
protein). CSA and CSB are involved in TC NER. 
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A third NER-related disorder is TTD. While symptoms vary, the disease is characterized 
by brittle hair, dry skin, and developmental/neurological deficiencies65. About 75% of patients 
exhibit ichthyosis and about 50% exhibit photosensitivity63,65. TTD is caused by mutations in XPB, 
XPD, TTDA, or TTDN1. XPB, XPD, and TTDA are all subunits of TFIIH, involved in both 
transcription and damage verification during NER. The function of TTDN1 is less clear, and is 
associated with the non-photosensitive form of TTD. 
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Figure 1. Summary of eukaryotic nucleotide excision repair. 
Major changes to DNA during eukaryotic nucleotide excision repair are illustrated. The major proteins (not a 
comprehensive list) involved are indicated at the appropriate step. The potential involvement of XPA at various 
steps is indicated in purple. 
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1.3 XPA 
1.3.1  Structure and Disorder 
There is limited structural data for full-length XPA, due to large regions of conserved 
intrinsic disorder (Figure 2a), particularly in the N- and C-termini66-69. In the last 20 years, the 
study of intrinsically disordered proteins and protein domains has shown that lack of structure can 
actually be necessary for certain proteins to function70-72. Though diverse, many such disordered 
proteins are involved in molecular recognition73. Upon binding their target, disordered regions 
may fold and become structured74 or remain flexible75. It has been suggested that the intrinsically 
disordered regions of XPA may play a role in binding to DNA and/or other NER proteins69.  
The human XPA protein contains 273 amino acids with a molecular weight of 31.4 kDa. 
The minimal DNA-binding domain (DBD) was first identified by Tanaka and colleagues76, and 
later expanded to include residues 98-239 (ref. 77), covering about half of the total protein length 
and including a zinc-finger motif76,78-81. Available structures are restricted to the DBD, including 
early solution NMR studies of human XPA50,82,83 (Figure 2b), a recent crystal structure of the 
extended human DBD84 (Figure 2c), co-crystal structures of yeast Rad14 (XPA homolog) on 
damaged DNA85,86 (Figure 2d), and a cryo-electron microscopy structure of XPA bound to DNA 
with TFIIH87 (Figure 2e). These structures all indicate the presence of a basic cleft, or cluster of 
positively charged residues (Figure 2c), presumably involved in binding the negatively charged 
backbone of DNA68,83,88.  
The Rad14 minimal DBD structures suggest that XPA binds as a dimer flanking the site of 
damage and produces a 70° bend in the DNA85,86. XPA stoichiometry, both on and off of DNA, 
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remains controversial. The Rad14 structure supports previous studies which concluded that XPA 
binds DNA as a homodimer89,90. Other reports indicate that XPA binds DNA as a monomer68,87. 
Finally, a combination of structural studies and biochemistry (EMSA48, gel filtration 
chromatography66, and circular dichroism91) have suggested that XPA binding to damaged DNA 
induces conformational changes in the protein that are associated with different binding modes. 
Although DNA bending was not measured directly in these studies, the observed binding modes 
may reflect the formation of protein-DNA complexes containing bent DNA and stably bound 
XPA. Recent molecular dynamics simulations of docking between XPA residues 98-210 (PDB 
1XPA) and bent 10bp dsDNA containing a CPD (PDB 1N4E) shows formation of increased 
secondary structure in XPA compared to the free protein simulations92.  
1.3.2  XPA-DNA Interactions 
In support of a damage recognition role for XPA, there is substantial evidence for the 
protein’s specificity to several definitive substrates for NER. Some of the earliest studies 
demonstrated XPA’s notable affinity for UV-irradiated DNA48,55,76,79,93,94, with reported 
specificities as high as 1,000-foldii (when calculated to account for non-specific bases in damaged 
 
ii Note that while it is nearly impossible, in part due to the effects of experimental method and ionic 
strength/buffer conditions on XPA-DNA binding90,95,96, to compare reported specificities between studies, I have 
attempted to do so in the most consistent manner possible. When the information is available, fold-specificities are 
reported as the difference in binding affinities between substrates—as published by the original authors—multiplied 
by the number of non-specific bases in the damaged substrate. In some cases, this is how the authors presented the 
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substrate)93 over non-damaged dsDNA. While some groups report no specificity of XPA for CPD 
lesions60,94, others have observed higher affinity for a CPD (~90-fold specificity) than non-
damaged DNA97. Furthermore, in all studies, XPA had a significantly higher affinity for 6-4PPs 
than for both CPDs and non-damaged DNA. In a side-by-side comparison of XPA and XPC, an 
established recognition protein in NER, the two proteins exhibited similar fold-specificity (~75-
fold) for a 6-4PP; XPC had a higher affinity for both damaged and non-damaged DNA, resulting 
in an analogous KD ratio
60. These data suggest that XPA prefers binding to a lesion which is more 
distorting to the DNA helix (i.e. to a 6-4PP, which induces a 44° bend, versus the less destabilizing 
CPD, which does not readily form a kinked structure)27. 
XPA binding to a variety of base adducts has also been of interest. XPA binds preferentially 
to AAF-adducted dsDNA over non-damaged dsDNA85,86,90,98,99. It does not, however, display this 
specificity when the AAF adduct is placed within a mismatched DNA bubble100. Furthermore, 
XPA has demonstrated specificity for a C8-aminofluorene (C8-AF) adduct and an N2-
acetylnaphthyl (N2-AAN) adduct, although not to the same degree as AAF86. While all three 
adducts destabilize the DNA helix and induce bending, the authors suggest that the preferential 
binding to dG-C8-AAF, compared to dG-C8-AF or dG-N2-AAN, might be due to the flexibility 
of the helix and the energy required to form a sharp bend when in complex with XPA; the two 
rings of the dG-C8-AAF lesion are in plane and able to intercalate/stack with adjacent bases, 
thereby stabilizing the helical kink85,86. 
 
data in their original reports.46,93,94 For fold differences as reported in original studies, please refer to Table 1 
(Appendix B). Also please note that not all authors provide quantitative comparisons for binding affinity. 
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XPA has increased affinity (up to ~250-fold reported101) for 1,2-GG cisplatin-adducted 
DNA76,79,94,96,101-103 over non-damaged DNA, but less than 100-fold specificity for 1,3-GTG 
cisplatin-adducted DNA101 and no specificity for a dinuclear analogue102. The 1,2-GG cisplatin 
intrastrand crosslink induces a rigid 30-35° bend in the DNA helix104,105. The 1,3-GTG cisplatin 
intrastrand crosslink induces a similar bend angle, but confers different thermodynamic properties 
to the helix101; the dinuclear analogue induces helical flexibility but not directional bending106. In 
an effort to test XPA affinity for different “rigid bends,” Zou and colleagues studied binding to 
DNA substrates with two-, three-, or four-carbon tethers connecting adjacent guanine bases100. 
These intrastrand crosslinks induce 30°, 11.7°, or 7.4° bends in the DNA helix, respectively107. 
Interestingly, no specificity was reported for XPA binding to any of these substrates100. These data 
suggest that a bend alone is not sufficient to enhance XPA binding; however, the presence of the 
carbon tether may impair the ability of XPA to test for DNA bending and form stable complexes 
with even sharper bends. 
One study reported no specificity of XPA for psoralen-treated dsDNA94. Psoralen is able 
to intercalate DNA, and upon UV treatment, forms covalent monoadducts at pyrimidine bases as 
well as diadduct interstrand crosslinks. A combination of studies have shown that the psoralen 
monoadduct has little impact on the DNA helix curvature or flexibility, and that while the diadduct 
does cause unwinding of the DNA about the lesion, it has little impact on helical secondary 
structure108,109. Additionally, XPA has demonstrated at least 50-fold specificity for dsDNA with a 
mitomycin C interstrand crosslink91,110. This lesion has also been reported to not significantly 
impact the DNA helix, but may cause some local bending or distortion111. It is possible that these 
low levels of specificity are only apparent under certain experimental conditions. Nonetheless, 
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compared to lesions which are known to cause significant DNA bending, XPA consistently 
demonstrates higher affinity. 
Other DNA modifications have been investigated to gain further insight into the structural 
and thermodynamic requirements for XPA specificity. In one study, XPA demonstrated no 
specificity for a C4’ pivaloyl DNA backbone adduct, which disrupts hydrogen bonding but does 
not distort the helix98. Others have reported preferential binding of XPA to dsDNA with a short 
bubble of three or four mismatched bases98,100,102, or a single-stranded loop of three nucleotides 
inserted into one strand of duplex DNA96,102, both of which do cause helical distortion. 
Additionally, XPA shows some specificity for DNA bases replaced with 5-nitroindole or 3-
nitropyrrole nucleoside analogs that maintain all properties of B-form DNA, except for Watson-
Crick hydrogen bonding98,102. Compared to these minor distortions, XPA binds avidly to three- 
and four-way dsDNA junctions, engineered to mimic helical kinks102,103. Although there has been 
no direct comparison of these substrates with NER lesions like AAF or 6-4PPs, the consensus 
appears to be that bent structures that maintain some amount of flexibility are recognized with the 
highest affinity by XPA. 
Additional studies revealed that XPA also binds preferentially to partially single stranded 
DNA and forked substrates that more closely resemble unwound NER intermediates. XPA has 
significantly higher affinity—up to 120-fold specificity, reported by one group77—for forked Y-
shaped substrates (i.e. ss/dsDNA junctions) than for non-modified dsDNA or ssDNA100,102,103,112. 
When compared to ds/dsDNA junctions, however, XPA has even higher affinity102,103. 
Furthermore, while these forked substrates could be considered as NER intermediates, they also 
represent structures that readily adopt a kinked DNA helix, and allow bending into the major 
groove, which might also mimic lesion substrates85. It is possible that, regardless of the step in the 
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NER pathway, XPA is able to recognize bent DNA structures and this property facilitates its role 
in damage recognition as well as in later steps. The common characteristic between “good” XPA 
substrates appears to be the ability to form a stable, sharply kinked conformation. 
For a more comprehensive summary of published biochemical studies on XPA affinity for 
different DNA substrates, please refer to Table 1 (Appendix B). For further discussion of the 
energetics of DNA bending and protein binding, please refer to Appendix D. 
1.3.3  XPA-Protein Interactions 
In addition to having binding specificity for damaged DNA on its own, the XPA has a well-
established role as a scaffold protein during DNA repair. A summary of major interactions reported 
in the literature is outlined in Table 2 (Appendix C). These have largely been studied using yeast 
two-hybrid, pull-down assays, and other biochemical methods. XPA’s potential roles in multiple 
steps of the NER pathway are indicated by its interactions with proteins involved in essentially 
every step of repair (Figure 2a). 
In support for an early role of XPA during damage recognition, interactions with both UV-
DDB (via DDB2)52,113 and XPC114,115 have been reported. XPA and XPC do not appear to interact 
together on DNA, suggesting that a hand-off may occur between these two proteins during 
repair116. However, Matsunaga and colleagues showed that XPA and UV-DDB bind damaged 
DNA together. Moreover, this interaction increases the affinity of both proteins for a CPD 
lesion113. These data were used by Mattaparthi and colleagues in a computational study to show 
that the interaction between DDB2 and XPA residues 185-226 is likely strong and transient, 
involving 7-9 salt bridges and 16-20 hydrogen bonds117. 
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XPA also likely plays an important role during damage verification; there is strong 
evidence supporting an interaction between XPA and TFIIH on DNA. Biochemical work48,118,119 
and a recent cryo-electron microscopy87 structure show that XPA interacts with multiple TFIIH 
subunits: XPB, XPD, p52, and p8/TTDA. Furthermore, the presence of XPA enhances TFIIH 
specificity for NER substrates by promoting translocation along non-damaged DNA61,62 but not at 
bulky cisplatin lesions43,44. 
The single-stranded binding protein RPA is thought to stabilize unwound DNA in the pre-
incision complex. Extensive biochemical and structural work has shown that XPA and RPA 
interact both on and off of DNA51,55,57,96,120-124. Specifically, XPA interacts with the subunits 
RPA32 and RPA70, but not RPA14. Both of these interactions appear to be mediated by the N-
terminus of XPA (upstream of the DBD). Mutations in XPA residues K141 and K179 impair 
binding to RPA70 but not to damaged DNA56. Furthermore, several groups report that RPA 
enhances the affinity of XPA binding to short damaged dsDNA substrates55,97,102, although there 
is some disagreement about the cooperativity of binding90,96. 
XPA interaction with the ERCC1-XPF endonuclease complex also places XPA in the pre-
incision or incision complex125. XPA is required for the recruitment of ERCC1/XPF to damaged 
DNA, and this appears to be mediated via direct interaction with residues 91-119 of ERCC149. In 
a filter binding assay, XPA demonstrated enhanced affinity for UV-irradiated DNA, but not non-
damaged DNA, in the presence of purified ERCC1126. A ternary complex of ERCC1 with XPA 
and RPA has also been observed122. Several other XPA-protein interactions have been reported 
with less clear implications for NER. These are included in Appendix C. 
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Figure 2. XPA structure and disorder. 
[a] Protein sequences of XPA homologs from multiples species were aligned using PROMALS3D127 and 
disorder predictions for each sequence were obtained via the PONDR VL-XT algorithm128. S.S., secondary 
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structure elements (triangles, beta sheets; cylinders, alpha helices) based on the NMR structure of the human 
XPA DBD (PDB 1XPA). Dom., conserved domains of human XPA protein (ZF, zinc finger; DBD, DNA-binding 
domain). Interact., some published interactions between XPA and NER proteins (see Appendix C); tan ovals 
represent XPA residues involved. [b-e] Major resolved structures of XPA and Rad14 DNA-binding domains 
(blue). [b] Solution NMR structure of the minimal DNA binding domain of human XPA (M98-N210) without 
DNA. PDB 1XPA. [c] Crystal structure of extended DNA binding domain of human XPA (M98-R231) without 
DNA. Right, structure is rotated and positively charged residues of basic cleft are colored red. PDB 6J44. [d] 
Co-crystal structure of yeast Rad14 DNA binding domain bound to DNA containing an AAF adduct (magenta). 
PDB 5A3D. [e] Cryo-electron microscopy structure of XPA bound (full-length protein used, residues I104-R237 
resolved) to DNA with TFIIH. TFIIH subunits: p8 (wheat), XPB (sage), XPD (teal), p44 (lime), p34 (mauve), 
p52 (raspberry). PDB 6RO4. 
1.4 Hypotheses and Scope 
Motivated by compelling reports in the literature that XPA is able to recognize DNA 
damage, and further encouraged by results obtained during this dissertation, we set out to resolve 
five fundamental issues regarding how XPA interacts with DNA and its mechanism of damage 
search. 
1. Does XPA have specificity for NER substrates? Numerous bulk studies have shown that 
XPA binds preferentially to DNA containing an AAF adduct or UV-photoproduct. We sought to 
demonstrate this specificity at the single molecule level. Atomic force microscopy (AFM) was 
used to show that XPA binds more frequently at an AAF adduct and single molecule fluorescence 
microscopy demonstrated that XPA pauses at UV-lesions in long DNA molecules. 
2. What is the stoichiometry of XPA binding to DNA? Based on the Rad14 co-crystal 
structure and several biochemical reports, we predicted that XPA would bind DNA lesions as a 
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homodimer. However, we also noted some potential flaws in the previous studies, including the 
use of short DNA substrates and artificially high protein concentrations. To answer the question 
of stoichiometry as directly as possible, we turned to atomic force microscopy, as it is uniquely 
able to distinguish between true dimer complexes and distinct binding events on the same DNA 
molecule129. We found that XPA binds DNA as a monomer at both damaged and non-damaged 
sites.  
3. What role does DNA bending have in damage search? Again, based on the Rad14 co-
crystal structure and the well-known importance of DNA bending for other repair proteins, we 
hypothesized that XPA would induce DNA bending as part of its target search. Atomic force 
microscopy offers a direct measure of DNA bend angles at specific sites (i.e. at a lesion or bound 
protein). As predicted, we found that (1) XPA has specificity for DNA lesions (in this case, AAF) 
that induce DNA bending and (2) that XPA bends DNA even further at both non-damaged and 
damaged sites.  
4. What modes of diffusion does XPA exhibit? We then sought to identify search strategies 
used by XPA, as discussed in Section 1.1. In order to gain insight into the dynamics of XPA 
damage search, we turned to single molecule fluorescence microscopy via the DNA tightrope 
assay. This was used to distinguish between three-dimensional and one-dimensional diffusion as 
well as well different modes of one-dimensional diffusion (short-range sliding and long-range 
hopping). We tested dose-dependent effects of DNA damage on XPA diffusive behavior. 
5. What role do the disordered N- and C-termini play in XPA-DNA interactions? Finally, 
we hypothesized that each mode we observed during XPA damage search on DNA corresponded 
to a distinct conformational state. Furthermore, we predicted that the intrinsically disordered N- 
and C-terminal arms of XPA participated in damage recognition and changing between 
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conformational states. To test this, DNA tightrope experiments were performed with a truncated 
form of XPA. 
Finally, we propose a model of XPA episodic motion in which different conformational 
states of the protein are associated with different modes of DNA target search and the presence of 
helix-distorting DNA damage stabilizes tighter binding. 
1.5 Approach: Single Molecule Methods for Studying Protein-DNA Interactions 
In order to address these questions and elucidate how XPA recognizes DNA damage we 
used two single molecule techniques. First, atomic force microscopy (AFM) was used to assess 
binding specificity, stoichiometry, and DNA bending. To accomplish this, a new PeakForce 
Tapping® AFM mode (Bruker) was validated for calculating the molecular weight of small 
proteins bound to DNA. Second, we used single molecule fluorescence microscopy to follow how 
quantum dot-labeled XPA interrogates DNA for damage in real time. Single molecule approaches 
offer unique advantages over bulk studies, discussed below and throughout this dissertation. A 
brief introduction to these methods is provided below. For further discussion on the uses, 
advantages, and limitations of AFM and the DNA tightrope assay, please refer to Appendix D 
(Studying Protein-DNA Interactions Using Atomic Force Microscopy), Appendix E (Dancing on 
DNA tightropes: Watching Repair Proteins Interrogate DNA in Real Time), and Appendix F 
(Single-Molecule Methods for Nucleotide Excision Repair: Building a System to Watch Repair in 
Real Time). 
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1.5.1  Atomic Force Microscopyiii 
Developed in the mid-1980’s, the atomic force microscope has become an increasingly 
powerful instrument for studying physical properties of materials on an atomic scale130. When 
studying protein-DNA interactions, it is important to keep in mind the forces that govern them. 
The four major interactions are: (1) hydrogen bonding between side chain and main chain amino 
acids and the floor of the major or minor groove of the DNA helix, (2) ionic interactions between 
the negatively charged phosphate backbone of DNA and positive amino acid side chains, (3) 
hydrophobic interactions and particularly pi stacking of DNA bases and aromatic side chains, and 
(4) Van der Waals forces over large surface areas131,132. 
The first reports of atomic force microscopy (AFM) imaging of protein-DNA complexes 
were in 1992 of the E. coli RNA polymerase complexed with DNA133 and of DNA polymerase on 
M13 phage DNA134. Since then, AFM has proven to have unique advantages in the study of 
protein-nucleic acid interactions. AFM imaging is relatively simple and the process allows for 
samples to remain under more physiological conditions. Relatively long DNA substrates may be 
used and there is no requirement for labeling, staining, or fixation of either the DNA or the protein. 
Most importantly, it provides direct imaging at the single molecule level, and thus rare events can 
be observed that would otherwise by obscured in bulk biochemistry techniques. 
 
iii This section (1.5.1 ) has been adapted from ref. 129. Please find the full text in Appendix D. Also refer to 
Appendix F for further discussion of AFM of nucleoprotein complexes. 
22 
1.5.2  DNA Tightrope Assayiv 
In order to understand how DNA repair proteins find damaged sites in a vast excess of non-
damaged DNA, the field of DNA repair has moved to various single molecule approaches allowing 
direct visualization of proteins interacting with their DNA substrates136. These single molecule 
techniques can provide unique insights into population trends without losing detailed information 
on individual particles or events137. An optical platform consisting of DNA tightropes was 
developed by Neil Kad at the University of Vermont and first used to study bacterial nucleotide 
excision repair (NER) proteins138,139 and base excision repair (BER) glycosylases140. This DNA 
tightrope assay takes a similar approach to the DNA curtain setup developed by Dr. Eric Greene 
and colleagues18,141 with one important difference. The tightrope itself is established by suspending 
long molecules of dsDNA (~90% contour length) between poly-L-lysine coated 5 micron beads 
dispersed in a flow cell. Visualizing repair proteins of interest up off the surface requires labels 
with bright fluorescent signals, and real-time imaging requires photostability over long periods. 
To accomplish these two needs, repair proteins are conjugated to quantum dots (Qdots) with 
appropriate antibodies and added to the flow cell. Interactions are recorded in real time, in the 
absence of flow, using oblique angle fluorescence on a total internal reflection fluorescence (TIRF) 
microscope with a CMOS or EECD camera142. 
 
iv This section (1.5.2 ) has been adapted from ref. 135. Please find full text in Appendix E. Also refer to 
Appendix F for further discussion of DNA tightrope assay. 
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2.0 Materials and Methods 
2.1 Protein Purification 
2.1.1  His-flXPA 
Full length, wild-type human XPA cDNA was cloned into the pIBA35 vector with an N-
terminal His tag. The plasmid was transformed into One Shot BL21(DE3)pLysS competent E. coli 
cells (Invitrogen). Cultures were grown in LB medium containing 100 μg/ml ampicillin and 34 
μg/ml chloramphenicol at 37°C until the OD600 reached ~0.6. At this point, expression was induced 
with 0.5 mM IPTG and 10 μM ZnCl2 and cultures continued to grow for 4 hours. Cells were 
harvested by centrifugation at 16,000 × g for 8 minutes at 4°C. All the following purification steps 
were performed on ice or at 4°C. Cell pellets were resuspended in His-XPA lysis buffer (25 mM 
Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM DTT, 10% (v/v) glycerol, 10 µM ZnCl2, and 30 mM 
imidazole), lysed by sonication, and the insoluble fraction was pelleted by centrifugation at 45,000 
× g for 45 minutes. The supernatant was loaded onto an equilibrated HisTrap HP nickel column 
(GE) and washed with 30 column volumes (CV) of His buffer A (25 mM Tris-HCl, pH 7.5, 100 
mM NaCl, 5 mM DTT, 10% glycerol, 10 µM ZnCl2, and 30 mM imidazole). The sample was 
eluted with a gradient of 0-100% in 10 CV, His buffer A to His buffer B (25 mM Tris-HCl pH 7.5, 
100 mM NaCl, 5 mM DTT, 10% glycerol, 10 µM ZnCl2, and 500 mM imidazole). Fractions 
containing XPA were pooled and loaded onto an equilibrated MonoQ column and washed with 5 
CV MonoQ buffer A (25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM DTT, 10% glycerol, and 10 
µM ZnCl2). XPA was eluted with a gradient of 0-100% in 15 CV MonoQ buffer A to MonoQ 
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buffer B (25 mM Tris-HCl, pH 7.5, 1 M NaCl, 5 mM DTT, 10% glycerol, and 10 µM ZnCl2). 
Fractions containing XPA were pooled, diluted with MonoQ buffer A, loaded onto an equilibrated 
Heparin column, and washed with 5 CV MonoQ buffer A. XPA was eluted with a gradient of 0-
100% in 35 CV MonoQ buffer A to MonoQ buffer B. Fractions containing XPA were pooled and 
loaded onto a size exclusion column (HiLoad 16/60 Superdex 200), which was equilibrated with 
the His-XPA SEC buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 5 mM MgCl2, 5 mM DTT, 5% 
glycerol, and 10 µM ZnCl2). XPA eluted as a single peak and peak fractions were pooled, 
aliquoted, and flash frozen in liquid nitrogen and stored at -80°C. 
2.1.2  His-flXPA-StrepII and His-truncXPA-StrepII 
Full length, wild-type human XPA cDNA was cloned into the pIBA43 vector with an N-
terminal His tag and C-terminal StrepII tag. To make truncated XPA mutant, the N- and C-termini 
were deleted from this plasmid (cloning by Gene Universal), leaving only residues 98-239. Both 
constructs were expressed and purified the same way. 
The plasmid was transformed into One Shot BL21(DE3)pLysS competent E. coli cells 
(Invitrogen). Cultures were grown in LB medium containing 100 μg/ml ampicillin, 34 μg/ml 
chloramphenicol, and 10 μM ZnCl2 at 37°C until the OD600 reached ~0.4. The temperature was 
then decreased to 16°C and growth was continued until an OD600 of ~0.6 was achieved. At this 
point, expression was induced with 0.2 mM IPTG and cultures continued to grow overnight. Cells 
were harvested by centrifugation at 5,000 × g for 30 minutes at 4°C. All the following purification 
steps were performed on ice or at 4°C and, between each step, samples were analyzed on 4-12% 
Bis-Tris SDS gels and stained with SimplyBlue SafeStain (Invitrogen). Cell pellets were 
resuspended in His-XPA-StrepII lysis buffer (50 mM potassium phosphate, pH 7.9, 200 mM KCl, 
25 
20 mM imidazole, 5% glycerol, 0.02% sodium azide, and EDTA-free Protease inhibitor cocktail), 
lysed by sonication, and the insoluble fraction was pelleted by ultracentrifugation at 147,000 × g 
for 2 hours. The supernatant was loaded onto an equilibrated HisTrap HP nickel column (GE) and 
washed with 30 CV His buffer C (3.5 mM KH2PO4, 46.5 mM K2HPO4, 200 mM KCl, 20 mM 
imidazole, 5% glycerol, and 0.02% sodium azide). The sample was eluted with a gradient of 0-
50%, His buffer C to His buffer D (3.5 mM KH2PO4, 46.5 mM K2HPO4, 200 mM KCl, 500 mM 
imidazole, 5% glycerol, and 0.02% sodium azide). Fractions containing XPA were pooled and 
loaded onto an equilibrated StrepTrap HP column with StrepTactin sepharose (GE) and washed 
with 50 column volumes Strep buffer A (50 mM Tris-HCl, pH 8.0, 200 mM KCl, and 0.02% 
sodium azide) and eluted with Strep buffer B (50 mM Tris-HCl, pH 8.0, 200 mM KCl, 5 mM 
desthiobiotin, and 0.02% sodium azide). Fractions containing XPA were pooled and dialyzed into 
His-XPA-StrepII SEC buffer (50 mM HEPES, pH 8.0, 200 mM KCl, 5 mM MgCl2, 5 mM DTT, 
10% glycerol, and 0.02% sodium azide). Size exclusion chromatography was performed using the 
AKTA FPLC on a HiLoad 16/60 Superdex 200 column (Amersham). XPA eluted as a single peak 
and peak fractions were pooled, aliquoted, and flash frozen in liquid nitrogen and stored at -80°C. 
His-XPA-StrepII and His-XPA were compared by EMSA and AFM to confirm that the addition 
of the StrepII tag did not affect protein behavior. 
His-flXPA was used in all AFM experiments and some DNA tightrope experiments. His-
flXPA-StrepII was used for all electrophoretic mobility shift assays, multiangle light scattering, 
and some DNA tightrope experiments. To verify that both protein preparations exhibited similar 
behavior, they were compared by AFM with respect to the following parameters: binding position 
on AAF538, induced DNA bend angle, and AFM volume (Figure 3a-d). Because His-flXPA-StrepII 
has a slightly higher molecular weight than His-flXPA, His-flXPA-StrepII results were only used 
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for validation and were not combined with His-flXPA results for AFM experiments. Since both 
preparations behaved similarly in our AFM studies, we combined the data obtained in the DNA 
tightrope experiments. 
2.2 Multiangle Light Scattering 
Multiangle light scattering combined with size exclusion chromatography (SEC-MALS) 
of purified His-flXPA-StrepII in His-XPA-StrepII SEC buffer was performed as previously 
described143,144. 
2.3 DNA Substrate Preparation 
2.3.1  AAF37 Oligo 
The 37 nt oligonucleotide containing one dG-C8-AAF lesion (AAF37-top, sequence below) 
was a gift from Thomas Carell, prepared as published85. 
2.3.2  37 bp DNA Duplexes for EMSA 
ND37 was prepared by annealing ND37-top and FAM37-bottom. AAF37 was prepared by 
annealing AAF37-top and FAM37-bottom. CPD37 was prepared by annealing CPD37-top and 
CPD37-bottom. Annealing reactions contained 1.25 μM top strand, 1 μM bottom strand, 10 mM 
Tris-HCl, pH 8.0, and 100 mM KCl. Reactions were incubated at 95°C for 5 minutes then cooled 
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slowly to room temperature Oligonucleotide sequences (all purchased from IDT except AAF37-





CPD37-bottom: 5’-6FAM- ATTTGACTCCCATGGAATCGCTGCAGGAATGACTCGG 
2.3.3  Defined Lesion Plasmids 
Plasmids containing single site-specific dG-C8-AAF adducts were prepared as described 
previously (see Appendix F for a detailed protocol)21,142. Briefly, purified pSCW01 plasmids were 
nicked by Nt.BstNBI to create a 37-base gap. A 37mer containing a single dG-C8-AAF (AAF37-
top, above) was annealed into this gap and the backbone was sealed with T4 DNA ligase. 
2.3.4  DNA Duplexes for AFM 
Substrates for AFM were prepared as described previously (see Appendix F)142. 
Essentially, a 538 bp DNA fragment was cut out of either unmodified pSCW01 plasmid (for 
ND538) or pSCW01 with a site-specific dG-C8-AAF lesion, described above (for AAF538). The 
plasmid was incubated with restriction enzymes XmnI and PciI, cutting 372 bp 5’ to and 165 bp 
3’ to the lesion, respectively. Nick514 was prepared by amplifying a 514 bp fragment from the 
pSCW01 plasmid and treating with Nt.BspQI to create a nick at 36% of the DNA contour length. 
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2.3.5  Long DNA Substrates for Tightrope Assay 
The NDλ substrate was prepared by diluting λ genomic DNA (NEB) to 50 ng/μl in 10 mM 
Tris-HCl, pH 8.5. The UVλ20J substrate was prepared by treating NDλ with 20 J/m
2 of UV-C 
radiation (254 nm). A qPCR assay was performed previously to confirm the presence of UV 
photoproducts (6-4 PPs and CPDs) at a density of ~1 lesion per 2.2 kbp21. To prepare UVλ80J and 
increase the lesion density such that there was ~1 lesion per 550 bp (i.e. 1 6-4PP every 2.2 kbp), 
NDλ was treated with 80 J/m2 of UV-C. The dG-C8-AAF arrays were prepared as described 
previously (see Appendix F)21,142, using the defined lesion plasmid described above. Lesion-
containing pSCW01 was linearized via restriction digest by XhoI (NEB) then incubated with T4 
DNA ligase (NEB) to achieve long (> 40 kbp) tandemly ligated products with one dG-C8-AAF 
every 2 kbp. 
2.4 Electrophoretic Mobility Shift Assay 
XPA-DNA reactions were prepared by combining 8 nM 37 bp DNA with varying amounts 
of His-flXPA-StrepII in XPA EMSA buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM DTT, 
0.5 mg/ml BSA, and 5% glycerol) in a final reaction volume of 10 μl. Each reaction was incubated 
for 25 minutes at room temperature then immediately loaded on two pre-run 5% non-denaturing 
polyacrylamide gels (37.5:1 acrylamide:bis). Both pre-run and run were performed at 4°C, in 0.5X 
TBE buffer (44.5 mM Tris, 44.5 mM boric acid, 1 mM EDTA, pH 8.4), at constant voltage (90 
V). DNA bands were visualized using a laser scanner for fluorescence (Typhoon, Amersham). 
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Gel images were quantified by measuring signal intensities of each band (ImageJ, NIH). 
The percentage of DNA bound was determined by dividing the intensity of the shifted (“bound”) 
DNA by the sum of all bands in a lane. These values were plotted against XPA concentration and 
the data were fit to the following equation via nonlinear regression (GraphPad Prism): 
 
% 𝐷𝑁𝐴 𝐵𝑜𝑢𝑛𝑑 = 100 ×  
(𝑃 + 𝐷 + 𝐾𝐷) − √(𝑃 + 𝐷 + 𝐾𝐷)2 − 4𝑃𝐷
2𝐷
 Equation 1 
where KD is the equilibrium dissociation constant, P is the total protein concentration, and D is the 
total DNA concentration. This model was chosen because our experimental conditions required 
that the DNA concentration be in the same molar range as the KD (ref. 
145,146). 
2.5 Atomic Force Microscopy 
2.5.1  Sample Preparation 
Samples for AFM were prepared as previously described (see Appendix F)142. All buffers 
and solutions were first filtered through 0.02 μm sterile filters (Whatman). For imaging of free 
proteins or free DNA (i.e. no reaction), the sample was diluted to either 40 nM (protein) or 4 nM 
(DNA) in AFM deposition buffer (25 mM HEPES, pH 7.5, 25 mM NaOAc, and 10 mM 
Mg(OAc)2) which had been pre-warmed to 65°C and brought back to room temperature. XPA-
DNA reactions consisted of 100 nM 538 bp DNA (ND538 or AAF538) and 0.6-4 μM His-flXPA in 
XPA AFM buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 5 mM MgCl2, 10 μM ZnCl2, 5 mM 
DTT, and 5% glycerol) in a total volume of 10 μl. APE1-DNA and Polβ-DNA reactions consisted 
of 100 nM 514 bp DNA (Nick514) and 500 nM protein in APE1 buffer (50 mM HEPES, pH 7.5, 
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150 mM NaCl, 10 mM MgCl2) in a total volume of 10 μl. Each binding reaction was incubated for 
30 minutes at room temperature then diluted 1:25 in AFM deposition buffer. 25 μl droplets were 
deposited on freshly cleaved mica, allowed to equilibrate for 30 seconds with gentle rocking, then 
washed with 1 ml of filtered H2O and dried under a gentle stream of nitrogen gas. 
2.5.2  Data Collection 
All AFM images were obtained using ScanAsyst PeakForce Tapping mode in air on a 
Multimode V Microscope with an E scanner (Bruker). Samples were scanned with a triangular tip 
with a nominal radius of 2 nm, mounted on a silicon nitride cantilever (SCANASYST-AIR, 
Bruker). Probes were replaced for each new experiment or more frequently as needed. 1 × 1 micron 
images were collected at a resolution of 512 × 512 pixels and a scan rate of 0.977 Hz. Peak force 
setpoint was 0.01988 V. 
2.5.3  Data Analysis 
2.5.3.1 Free protein standard 
To generate the standard curve relating AFM volumes to molecular weight, analysis was 
performed on AFM images with the isolated protein samples. The following proteins of known 
MW were used: recombinant human HMGB1 (Abcam), His-tagged human APE1 (gift from Sam 
Wilson), His-tagged human DNA polymerase β (gift from Sam Wilson), and His-tagged UvrD 
(purified as published147). Particle dimensions were measured using Image SXM software and 
used to calculate volumes: 
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 𝑉 = 𝐴 × (𝐻 − 𝐵) Equation 2 
where V is the particle volume, A is the area of the particle footprint (determined via a set density 
threshold above background noise), H is the mean height of the particle, and B is the background 
height of the overall image148. 
2.5.3.2 Intrinsic DNA bend angle 
To determine the intrinsic bend angles of DNA substrates at 30% from each end, AFM 
images containing only the DNA were analyzed. DNA molecules used in this analysis had to be 
completely visible and isolated (i.e. not continuing past the edge of the image nor overlapping with 
itself or another molecule) and the total contour length must be within the range of ± 10% of the 
expected length. Measurements were done on TIF images using ImageJ software (NIH). The total 
DNA contour length was first measured and points at 30% from both ends were marked. Local 
bend angles at these sites were measured and are reported as the supplementary angle, θ (Figure 
11). 
2.5.3.3 Protein-DNA complexes 
In addition to the criteria for usable DNA molecules (above) analysis of protein-DNA 
complexes first required the identification of bound proteins using the following criteria: (a) the 
height of the complex must be greater than the average height of the DNA molecule and (b) the 
complex width must be greater than the average width of the DNA molecule. 
Methods for measuring protein binding position and induced DNA bend angle using 
ImageJ software (NIH) have been described in detail142. Briefly, binding position was determined 
by dividing the contour length of the DNA molecule from the center of a bound protein to the 
closest DNA end by the total DNA contour length. XPA-induced DNA bend angles were measured 
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at sites of bound XPA. In cases where two or more proteins were bound to the same DNA 
molecule, angles were not measured. 
Specificity calculations from protein binding positions were performed as published by 
Erie and colleagues149. Histogram showing distribution of protein binding position between 0 and 






. Specificity (S) was calculated as: 
 𝑆 = 𝑁 ∗
𝐴𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
𝐴𝑛𝑜𝑛−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ 1 Equation 3 
where N is the number of potential binding sites using an estimate of 8 bp (ref. 150) for the DNA 
footprint of XPA (N = 538 bp – 8 bp + 1 = 534 bp) and Aspecific and Anon-specific are the areas under 
the curve representing specific and non-specific binding, respectively (Figure 6).  
To measure protein volume when bound to DNA, the DNA volume was estimated and 
subtracted from the total complex volume (Figure 9a). Image SXM software was used to trace the 
perimeter of the complex. The length of the DNA through this space was projected assuming that 
the DNA runs through the center of the complex. Then, two unbound regions of DNA on either 
side of the complex, with lengths corresponding to that of the complex, were delineated. In cases 
where the protein was bound near the end of the DNA or near another protein, two unbound regions 
of DNA were chosen at other available locations on the same molecule. Volumes of all three 
regions (complex, DNA1, and DNA2) were determined as above (Equation 2). Protein volume 
was determined as the total complex volume minus the average of the two unbound DNA volumes:  
 𝑉𝑝𝑟𝑜𝑡𝑒𝑖𝑛 = 𝑉𝑐𝑜𝑚𝑝𝑙𝑒𝑥 −
𝑉𝐷𝑁𝐴1 + 𝑉𝐷𝑁𝐴2
2
 Equation 4 
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Histograms of all AFM results were plotted and Gaussians were fit to the data by nonlinear 
regression in GraphPad Prism. The number of histogram bins correspond to the square root of the 
sample size. 
2.6 DNA Tightrope Assay 
2.6.1  Flow Cell Set-Up 
All steps for reagent/material preparation, flow cell set-up, protein labeling, imaging, and 
data analysis for the tightrope assay have been described in detail (Appendix F)142 according to 
methods developed previously138,140. Briefly, flow cells were prepared by attaching slides with 
inlet/outlet tubing to PEGylated coverslips via tape spacers. Flow cells were incubated in blocking 
buffer (10 mM HEPES, pH 7.5, 50 mM NaCl, and 1 mg/ml BSA) for 10 minutes, then poly-L-
lysine coated silica microspheres (5 μm diameter) were flowed in and dispersed across the 
coverslip. Long DNA substrates were suspended between beads using continuous hydrodynamic 
flow with alternating direction in tightrope buffer (20 mM HEPES, pH 7.5, 50 mM NaCl, 3 mM 
MgCl2). 
2.6.2  Protein Labeling 
His-flXPA, His-flXPA-StrepII, or His-truncXPA-StrepII was labeled with either 705 nm 
or 605 nm quantum dots (Qdots). The former strategy was accomplished by first incubating 
streptavidin-coated 705 Qdot (Invitrogen) with biotinylated anti-His antibody, at a final 
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concentration of 167 nM Qdot and 833 nM antibody. Then, this mixture was incubated with an 
equal volume of 167 nM XPA; the final XPA concentration was 83.3 nM. The latter strategy was 
accomplished by first incubating XPA with a mouse monoclonal anti-His antibody, both at a final 
concentration of 200 nM. Then, this mixture was incubated with an equal volume of 1 μM 605 
Qdot conjugated to an anti-mouse secondary antibody (Invitrogen); final XPA concentration was 
100 nM. Labeled protein mixtures were diluted 4:100 in XPA tightrope buffer (25 mM HEPES, 
pH 8.3, 100 mM KCl, 1 mM EDTA, 0.545 mg/ml BSA, 1 mM DTT, and 10% glycerol). The final 
XPA concentration in the flow cell was 3-4 nM. To check for background binding by the Qdots or 
antibodies, controls were performed using the above conjugations with buffer instead of XPA. To 
verify that the two different Qdot labeling strategies did not impact results, the behavior of XPA 
labeled with either the 605 Qdot or 705 Qdot was compared on UVλ20J tightropes, showing no 
significant difference (Figure 3e). 
For 150 mM NaCl experiments, 150 mM NaCl buffer (25 mM HEPES, pH 7.5, 150 mM 
NaCl, 1 mM DTT, and 0.1 mg/ml BSA) was used in place of XPA tightrope buffer. For 1 M NaCl 
experiments, stationary particles of XPA were recorded in XPA tightrope buffer and, during 
recording, the buffer in the flow cell was replaced with 1 M NaCl buffer (1 M NaCl, 20 mM 
HEPES, pH 8.3, 80 mM KCl, 0.8 mM EDTA, and 8% glycerol), taking ~40 s of flow. 
2.6.3  Data Collection 
Movies of XPA-DNA interactions were recorded on an inverted fluorescence microscope 
(Nikon Ti) with 100X oil-based high-NA objective for TIRF-M and high-speed sCMOS camera 
(Andor). Qdots were excited with a 488 nm laser at an optimal oblique (sub-TIRF) angle and 
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visualized without an emission filter. Movies were taken for 5 minutes with frame rates between 
~10 and ~12.5 fps. 
2.6.4  Data Analysis 
Movie files were converted to a time series of individual TIF files (NIS-Elements, Nikon) 
and imported into ImageJ (NIH). Kymographs were generated using the slice function over the 
trajectory of the particle along the DNA. These were processed by FFT bandpass filtering to reduce 
noise (filter range 3-40 pixels, with suppression of vertical stripes). A Gaussian Fit plugin was 
used to fit the fluorescence intensity in the kymograph to a one-dimensional Gaussian at each point 
along the x-axis (i.e. each frame or time point)138. Fitting data was processed using custom scripts 
in MATLAB (MathWorks) to exclude poorly fitted positions and convert particle position from 
pixels to nm. 
First, each particle (i.e. one kymograph, 5 minute observation) was categorized based on 
whether it moved at all during the observation window (stationary vs. motile) and whether it 
dissociated during recording (persistent vs. dissociated). Dissociation was defined as the 
disappearance of Qdot-XPA for at least 200 frames (~20 seconds). We have previously reported 
that the mean positional accuracy for a 605 nm Qdot bound to biotin is 6 ± 3 nm by Gaussian 
fitting of the fluorescence intensity to a point spread function21. The position uncertainty over time 
has been determined to be 36 ± 3 nm (~100 bp), accounting for stage drift, DNA movement, and 
thermal fluctuations21. We used a conservative cutoff of 130 nm (three pixels, ~400 bp) to classify 
motile particles22,23. 
Motile particles were analyzed further for different modes of diffusion. Each kymograph 
was broken down into phases, falling into three possible modes of behavior: paused (particle 
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displacement not varying more than 130 nm), short-range diffusion (displacement between 130 
nm and 690 nm), and long-range diffusion (displacement greater than 690 nm). Shorter range 
modes were only allowed to interrupt longer range modes if they persisted for at least 5 seconds. 
For example, if a particle was exhibiting short-range behavior, paused (i.e. stationary) for 10 
seconds, then went back to short-range behavior, this would be counted as three phases; if the 
pause only lasted 2 seconds, this would be counted as a single short-range phase. If a particle was 
paused prior to recording, the first phase of a kymograph may be less than 5 seconds. Each motile 
particle was analyzed with respect to the following parameters: position range, phase switch rate, 
lifetime of each phase, and number of pause sites. 
The mean squared displacement (MSD) was calculated for all motile phases (short-range 









 Equation 5 
where N is total number of frames in the phase, n is the number of frames at a given time step, Δt 
is the time increment of one frame, and xi is the particle position in the ith frame
151. The diffusion 
coefficient (D) was determined by fitting a linear model of one-dimensional diffusion to the MSD 
plots: 
 𝑀𝑆𝐷(𝑛∆𝑡) = 2𝐷(𝑛∆𝑡) + 𝑦 Equation 6 
where y is a constant (y-intercept). Fittings resulting in R2 less than 0.8 or using less than 10% of 
the MSD plot were not considered. 
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2.6.5  Calculation of Theoretical Constants 
Calculations to determine the theoretical limit of the diffusion coefficient and the energy 
barriers to free diffusion were pursued as described22,138. All calculations were done based on the 
streptavidin-coated 705 Qdot labeling strategy, although similar results are obtained for 605 Qdot 
conjugated to a secondary antibody. First, the hydrodynamic radii of full-length human XPA (3.3 
nm, ref. 94) and the streptavidin-coated 705 Qdot (12.8 nm, ref. 152) were used to estimate the 
hydrodynamic radius of Qdot-labeled XPA (Reff = 12.873 nm).  
Treating the labeled protein as a sphere allows us to define the diffusion coefficient (D) 




 Equation 7 
where kB is the Boltzmann constant (1.38 J/K), T is the temperature (298 K), and ξ is a friction 
term. The friction term for a protein sliding along DNA following the corkscrew path of the helix, 
described by Schurr153 and modified slightly154, is defined as: 







2) Equation 8 
where η is the viscosity of the medium (0.89 × 10-2 poise), BP is the distance between two DNA 
base pairs (0.34 nm), and ROC is the off-center distance from the protein center of mass to the DNA 
helical axis (Reff + 1 nm = 13.873 nm). Combining Equation 7 and Equation 8 permits calculation 
of the diffusion coefficient of Qdot-labeled XPA sliding along DNA with no energy barrier, or the 















Using the variables defined above for Qdot-labeled XPA, Dlim = 1.54 × 10
-2 μm2/s. 
The energy barriers to free diffusion (EA) can be calculated using the Arrhenius 
relationship: 




 Equation 10 
where k is the rate constant (in this case, the stepping rate 2D/BP2) and EA is the activation energy 
of the reaction. The energy barrier to free diffusion is the difference between the theoretical 
(“barrier-less”) EA and the experimentally determined EA. By rearranging Equation 10 and 
substituting for k, this difference can be calculated: 
 Δ𝐸𝐴 = 𝑙𝑛 (
𝐷𝑙𝑖𝑚
𝐷𝑒𝑥𝑝𝑡
) × 𝑘𝐵𝑇 Equation 11 
where Dexpt is the experimentally determined D. Because the ΔEA can also be used to describe the 
roughness of the energy landscape, this value may also be referred to as σ (ref. 5). XPA undergoing 
short-range linear diffusion had a mean D of 2.49 × 10-3 μm2/s (Figure 13b), thus permitting the 
calculation of the energy barrier to diffusion via Equation 11, ΔEA = 1.57 × kBT. The diffusion 
coefficient for XPA the long-range mode (3.67 × 10-2 μm2/s) exceeds the theoretical limit of a 





Figure 3. Comparison of XPA preparations and Qdot labeling strategies. 
[a] Box and whisker plot (5-95 percentile) showing binding position on AAF538 of internally-bound His-XPA (n 
= 217, data reproduced from Figure 5e for comparison) and His-XPA-StrepII (n = 33). ns, p = 0.4810 by two-
tailed Student’s t test (p = 0.4628 by F test to compare variances). [b] Box and whisker plot (5-95 percentile) 
showing DNA bend angles at all sites of internally bound XPA on AAF538. Results obtained with His-flXPA (n 
= 181, data reproduced from Figure 11h for comparison) and His-flXPA-StrepII (n = 32) are shown. ns, p = 
0.4996 by two-tailed Student’s t test (p = 0.8013 by F test to compare variances). [c] Box and whisker plot (5-95 
percentile) showing AFM volumes of His-flXPA (n = 235, data reproduced from Figure 10d) and His-flXPA-
StrepII (n = 35) on AAF538. ns, p = 0.2289 by two-tailed Student’s t test (p = 0.0001 by F test to compare 
variances). [d] Percentage of His-flXPA (n = 277, data reproduced from Figure 5c for comparison) and His-
flXPA-StrepII (n = 42) bound to DNA at ends (lavender) or internally (tan) on AAF538. ns, p = 0.9728 by χ2 test. 
[e] Stacked bar graph showing the fraction of motile (teal) vs. stationary (white) and persistent (solid) vs. 
dissociating (diagonal lines) His-flXPA particles on UVλ20J tightropes. Results obtained with 605 Qdot (n = 107) 
and 705 Qdot (n = 34) labeling strategies are shown (see Section 2.6.2 Protein Labeling). Data reproduced as a 
sub-set of Figure 12b. ns, p = 0.4214 by χ2 test. 
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3.0 Results 
3.1 XPA Binds Specifically to a dG-C8-AAF Lesion 
We first confirmed that XPA recognizes AAF by electrophoretic mobility shift assay 
(EMSA) as reported by others85,90,98,99. We generated binding isotherms of XPA by incubating a 
37 bp DNA duplex (8 nM) with or without a single dG-C8-AAF adduct (AAF37 and NDF37, 
respectively) and increasing amounts of purified full-length human XPA (His-flXPA-StrepII, 
Figure 4a). The apparent equilibrium dissociation constant (KD) was 253.3 ± 14.2 nM for ND37 
and 109.0 ± 4.6 nM for AAF37, an approximately 2.3-fold difference (Figure 4d,f). Because AAF37 
contains only one specific site among 36 undamaged bp, this difference can be multiplied by a 
factor of 37 to account for non-specific binding to the AAF37 substrate
3,46,94. This results in 
approximately 85-fold specificity for dG-C8-AAF over non-damaged DNA, in good agreement 
with a previously reported specificity of XPA for 6-4PP46. In this way, we also found the specificity 
for a CPD lesion to be ~44-fold (Figure 4h). Furthermore, at higher XPA concentrations, a second 
band of higher molecular weight appeared, presumably indicating binding of a second XPA 
protein. It is important to note that any affinity of XPA for DNA ends could obscure EMSA results 
in terms of (a) specificity, as end-binding would increase overall binding on both substrates, 
thereby lowering the apparent specificity for the lesion, and (b) stoichiometry, as separate XPA 
proteins bound to the lesion and the end of the DNA would migrate the same as a true dimer in the 
gel. 
We therefore turned to AFM to study XPA binding to a 538 bp DNA substrate with or 
without a single dG-C8-AAF lesion. The small size of XPA presents challenges in terms of 
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resolution and ability to visualize XPA bound to DNA using AFM in tapping mode; we thus 
adopted the use of PeakForce Tapping mode (Bruker) with a 2 nm tip to achieve improved 
resolution and reduced sample deformation155-157. Using this method, we were able to clearly 
recognize XPA bound to DNA by the increased AFM height and width of the complex. 
Full-length human XPA (His-flXPA, Figure 4a, 1-4 μM) was incubated with a non-
damaged 538 bp DNA substrate (ND538, 100 nM in dsDNA fragments) and three-dimensional 
images were obtained using PeakForce Tapping AFM (Figure 5a). Of all the complexes observed, 
33% were bound to the ends of the DNA substrate (Figure 5c). For the remaining internally-bound 
proteins, position along the DNA molecule was measured as a percentage of the total contour 
length of the DNA. XPA position revealed no preference for a specific internal site (Figure 5d). 
XPA (His-flXPA) was then incubated with a 538 bp DNA substrate of the same sequence 
as ND538 but with a single dG-C8-AAF lesion at 30% from the 3’ end (AAF538, Figure 5b). On this 
substrate, only 22% of bound XPA proteins were found at the DNA ends. We also observed an 
increased frequency of complexes found near the lesion, at the expense of end-binders and other 
non-specific complexes (Figure 5e). A Gaussian was fit to the distribution of binding positions 
with mean 32.8 ± 12.3%. This spread of values is similar to others we have reported for lesion-
binding proteins22. As published by Erie and colleagues, a Gaussian model with an additional term 
accounting for non-specific binding can be fit to position data obtained from AFM experiments 
and used to assess specificity without confounding end-binders149. Following their calculations, 
we find that XPA has a specificity for dG-C8-AAF of about 660 (see Section 2.5.3.3, Figure 6). 
Based on these data, it is clear that XPA is able to bind non-specifically to DNA (at ends and non-
damaged sequences). However, the protein does exhibit specificity for the AAF adduct and binds 
preferentially at such a site. 
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Figure 4. Purification and DNA binding activity of human XPA. 
 [a] SDS-PAGE and Coomassie stain of purified full-length XPA (flXPA) and a truncated variant containing 
residues M98 through T239 (truncXPA). Left, His-flXPA-StrepII (loading amounts: 270 ng, 540 ng, 1.08 μg). 
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Center, His-flXPA (160 ng, 490 ng, 1.14 μg). Right, His-truncXPA-StrepII (110 ng, 230 ng, 340 ng). Ladders 
shown from same gel with irrelevant lanes cut out. [b] Chemical structure of N-(2’-deoxyguanosin-8-yl)-2-
acetylaminofluorene (dG-C8-AAF). [c] Chemical structure of a cyclobutane pyrimidine dimer (CPD). [d] Left, 
representative EMSA gel showing flXPA binding to a 37 bp DNA substrate with a 5’ fluorescein label (ND37). 
Right, quantification of five experimental repeats (each run on duplicate gels) plotted as mean ± range. The 
equilibrium dissociation constant (KD) was determined by a global fit to the data (see Section 2.4 for model) and 
is reported as best fit value ± s.e. of the fit. [e] Left, representative EMSA gel showing truncXPA binding to 
ND37. Right, quantification of two experiments (run on duplicate gels) plotted/fit as in d. [f] Left, representative 
EMSA gel showing flXPA binding to a 37 bp DNA substrate with a central dG-C8-AAF adduct and a 5’ 
fluorescein label (AAF37). Right, quantification of four experimental repeats (each run on duplicate gels) 
plotted/fit as in d. [g] Left, representative EMSA gel showing truncXPA binding to AAF37. Right, quantification 
of two experiments (run on duplicate gels) plotted/fit as in d. [h] Left, representative EMSA gel showing flXPA 
binding to a 37 bp DNA substrate with a central CPD lesion and a 5’ fluorescein label (CPD37). Right, 
quantification of three experimental repeats (each run on duplicate gels) plotted/fit as in d. [i] Left, 
representative EMSA gel showing truncXPA binding to CPD37. Right, quantification of two experiments (run 
on duplicate gels) plotted/fit as in d. [j] Residuals and R2 values for binding isotherm fittings of EMSA 
experiments, panels d–i. Residuals are plotted as mean ± range for each experiment (run on duplicate gels), 




Figure 5. XPA binds specifically to a dG-C8-AAF lesion. 
 [a-b] Representative AFM image of XPA bound to a non-damaged 538 bp DNA substrate (a, ND538) or a 538 
bp DNA with a single dG-C8-AAF lesion at 30% from one end (b, AAF538). Color scale represents AFM height 
and applies to panels a-b. White scale bar, 50 nm. The dashed white line indicates the example in the cartoon 
below. Binding position was measured between the center of the protein to the closest DNA end as a percentage 
of total DNA contour length. [c] Percentage of XPA bound to DNA at ends (lavender) or internally (tan) on 
ND538 (n = 163 particles) and AAF538 (n = 277 particles). * p = 0.0118 by χ2 test. [d] Histogram showing the 
distribution of internally bound XPA (n = 110 particles) position on ND538. End-binders are shown in lavender. 
[e] Histogram and Gaussian fitting of internally bound XPA (n = 217 particles) position on AAF538. End binders 




Figure 6. Specificity analysis of XPA binding position by AFM. 
 Histogram showing distribution of internally bound XPA on AAF538 (n = 217 particles, data reproduced from 
Figure 5e). To calculate specificity, a Gaussian model with an additional term for non-specific binding was fit 
to the data. Red (Aspecific), area under curve representing specific binding. Blue (Anon-specific), area under curve 
representing non-specific binding. See Section 2.5.3.3 for calculation details. 
3.2 XPA is a Monomer in Solution 
To resolve the question of XPA stoichiometry, we first sought to clarify the oligomeric 
status of the free protein. While there is support that XPA is a monomer in solution66,158,159, there 
have also been reports that it forms dimers and higher oligomers89. AFM has been successfully 
used to determine protein stoichiometry due to the linear relationship between AFM volumes of 
globular proteins and their molecular weight160,161. Full-length human XPA (His-flXPA, 32.6 kDa) 
was diluted to 40 nM and deposited on mica for imaging by PeakForce Tapping AFM in air. 
Volumes of the particles were measured and the data fit a Gaussian distribution centered at 30.3 ± 
15.4 nm3 (Figure 7a). 
In order to translate this volume into molecular weight, and thus protein stoichiometry, we 
generated a standard curve using monomeric proteins of known sizes (Figure 7b). HMGB1 (25 
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kDa), APE1 (37 kDa with His tag), DNA polymerase β (Polβ, 42.8 kDa with His tag), and UvrD 
(85.6 kDa with His tag) were adsorbed at 40 nM on mica and imaged by PeakForce Tapping AFM 
(Figure 8). Measured AFM volumes of these proteins were plotted against their known molecular 
weight and fit using least-squares linear regression: 𝑉𝑜𝑙𝑢𝑚𝑒 = (𝑀𝑊 × 1.14) − 2.00. Using this 
equation, the measured volumes for XPA correspond to 28.4 ± 15.3 kDa, close to the expected 
molecular weight of 32.6 kDa for the monomer. There was no significant population of XPA 
corresponding to the dimer size. These data suggest that, at 40 nM in solution, XPA exists as a 
monomer. 
To confirm that XPA is a monomer at higher protein concentrations, we performed size 
exclusion chromatography coupled with multiangle light scattering (SEC-MALS). At 65 μM and 
80 μM, purified XPA (His-flXPA-StrepII, 33.9 kDa) eluted in a single major peak, with a 
molecular weight corresponding principally to a monomer (Figure 7c). By both methods, the 
apparent molecular weight was a few kDa less than the theoretical value based on the sequence 
with tags, potentially due to protein conformation. Taken together, these data clearly indicate that 




Figure 7. XPA is a monomer in solution.  
[a] Top, representative 3D AFM image of free XPA. Color scale represents AFM height. Bottom, histogram 
and Gaussian fit of free XPA proteins imaged by AFM (n = 1,451 particles). Gaussian is labeled with mean and 
s.d. [b] Standard for calculating molecular weight from AFM volumes. Volumes of free proteins imaged by 
PeakForce Tapping AFM were calculated and respective histograms were fit by Gaussian distributions. Solid 
black circles, proteins used to generate the standard plotted against known MW (results and n values for each 
in Figure 8). Dashed line, linear regression, resulting in the calibration curve: Volume (nm3) = 1.14 × MW (kDa) 
– 2.00. R2 = 0.990. Purple arrows point to theoretical (thr.) volumes for the purified His-flXPA monomer (32.6 
kDa) and dimer (65.2 kDa). Open red square, experimental His-flXPA AFM volume (see a), corresponding to 
a molecular weight of 28.4 ± 15.3 kDa. Errors bars indicate s.d. of the Gaussian distribution. [c] Molar mass 
determination by SEC-MALS of XPA at 65 μM (green) and 80 μM (blue). Theoretical molecular weights for 
the purified His-flXPA-StrepII monomer (33.9 kDa) and dimer (67.8 kDa) are indicated by dashed lines 
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Figure 8. Generation of standard for AFM volumes. 
[a-d] Left, representative 3D AFM image and right, histogram and Gaussian fitting of AFM volumes used to 
generate the standard curve shown in Figure 7b. Gaussians are labeled with mean ± s.d. [a] HMGB1, 25 kDa. 
n = 943. Color scale represents AFM height and applies to all panels. White scale bar, 50 nm. [b] APE1, 37 kDa. 
n = 3,529. [c] Polβ, 42.8 kDa. n = 125. [d] UvrD, 85.6 kDa. n = 1,195. 
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3.3 XPA Binds Non-Damaged DNA and dG-C8-AAF as a Monomer 
Previous reports suggest that XPA may bind DNA as a homodimer89,90 while others have 
indicated monomeric binding68. AFM offers the unique ability to clearly distinguish between 
distinct complexes (e.g. one protein at a DNA end and one protein at a lesion) and true 
dimerization. Therefore, we measured the AFM volumes of XPA bound to DNA in order to 
determine stoichiometry. Because XPA is a small protein, we expected the DNA to contribute a 
significant amount of volume to the total complex. Some groups have considered this issue and 
have reported AFM volumes with the DNA portion subtracted163. Based on this idea, we developed 
a method to determine the size of the DNA within the complex and subtract its volume to obtain 
the volume of XPA alone (Figure 9a). 
It was important to validate that we would be able to use the standard curve based on free 
proteins (Figure 7b) to analyze the volumes of bound proteins. Using two proteins of similar size 
and known stoichiometry and the methods described, we were able to successfully determine 
molecular weights based on the standard. APE1 (37 kDa) was incubated with a 514 bp DNA 
substrate containing a nick at 36% from one end (Nick514) and imaged by AFM. The distribution 
of AFM volumes for APE1 on the DNA was centered at 40.6 ± 10.7 nm3 (Figure 9c). This is very 
close to the AFM volume obtained for the free protein (40.4 nm3, Figure 8b). Furthermore, using 
the standard curve, this corresponds to a molecular weight of 37.4 ± 11.2 kDa. Using our methods 
for DNA volume subtraction combined with the standard of free proteins, we were able to 
accurately estimate the molecular weight of APE1. We repeated this test using Polβ (42.8 kDa). 
Again, the protein was incubated with Nick514 and imaged by AFM. The distribution of AFM 
volumes was centered at 31.9 ± 16.1 nm3, which corresponds to 29.8 ± 15.9 kDa (Figure 9e) and 
was smaller than expected. The AFM volume of the free protein was 50.7 nm3 (Figure 8c), 
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suggesting that, in this case, we have over-estimated the contribution of the DNA to the total 
complex volume. This is a very likely explanation if the crystal structures of APE1 and Polβ are 
taken into consideration (insets, Figure 9c,e). APE1 is positioned on top of the DNA such that the 
volume of the complex is essentially the sum of the protein and the DNA alone, as our model 
assumes. However, Polβ pulls apart the nicked DNA backbone and inserts itself much further into 
the helix164; in this case, the volume of the complex appears to be less than the sum of the two 
parts. Overall, we can conclude that both APE1 and Polβ bind DNA as a monomer using our 
method, but it is important to note that the accuracy of molecular weight estimates is dependent 
on the precise conformation of the protein-DNA complex. 
Having confirmed that we would be able to distinguish XPA monomers and dimers on 
DNA, we measured AFM volumes for all XPA proteins (His-flXPA, 32.6 kDa) bound to the ND538 
and AAF538 substrates at multiple concentrations as high as 16-fold above the KD of XPA for 
damaged and non-damaged DNA (see Section 2.5.3.3, Figure 10a-b). In some cases, we observed 
multiple binding events on the same DNA molecule; these were measured individually if there 
was a clear stretch of unbound DNA between them. XPA bound to ND538 had a distribution of 
AFM volumes centered at 28.4 ± 12.7 nm3, corresponding to 26.7 ± 12.9 kDa (Figure 10c). The 
volumes of internally and end-binding proteins had similar distributions. XPA bound to AAF538 
had a distribution of volumes centered at 31.0 ± 12.9 nm3, corresponding to 29.0 ± 13.1 kDa 
(Figure 10d). Again, the volumes of internally- (either near the lesion or not) and end-binding 
proteins had similar distributions. These data suggest that, regardless of where XPA binds DNA, 
it does so as a monomer, which is consistent with an earlier study68. We did not observe a 
significant secondary population corresponding to the dimer. 
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Figure 9. Determination of DNA-bound protein AFM volume. 
[a] Schematic showing the steps used to subtract DNA volume from a protein-DNA complex. (1) Outline 
perimeter of the complex to separate it from unbound DNA. (2) Measure contour length of the DNA path 
through the complex. (3) Delineate regions of unbound DNA on either side of the complex with the same length 
measured in step 2. (4) Obtain AFM volumes for all three regions. (5) Protein volume is calculated as the volume 
of the complex minus the average DNA volume. [b] Representative 3D AFM image of APE1 bound to a 514 bp 
DNA substrate with a nick at 36% from one end (Nick514). [c] Left, histogram and Gaussian fitting of the 
distribution of calculated AFM volumes of APE1 on Nick514 (n = 100). The Gaussian is labeled as mean ± s.d. 
The AFM volume corresponds to 37.4 ± 11.2 kDa. Inset, crystal structure of APE1 bound to a nicked abasic 
DNA substrate (PDB 5DFF). Right, histograms and Gaussian fittings of measured volumes of unbound DNA 
and total complex. [d] Representative 3D AFM image of Polβ bound to Nick514. [e] Left, histogram and Gaussian 
fitting of the distribution of calculated AFM volumes (n = 131). The Gaussian is labeled as mean ± s.d. AFM 
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volume corresponds to 29.8 ± 15.9 kDa. Inset, crystal structure of Polβ bound to nicked DNA (PDF 1BPZ). 
Please see text for discussion of the underestimation of the protein size. Right, histograms and Gaussian fittings 




Figure 10. XPA binds non-damaged DNA and dG-C8-AAF modified DNA as a monomer. 
[a-b] Representative 3D AFM image of XPA bound to 538 bp non-damaged DNA (a, ND538) or 538 bp DNA 
with a single dG-C8-AAF adduct at 30% from one end (b, AAF538). White arrows point to XPA bound to DNA. 
Color scale represents AFM height and applies to panels a-b. [c] Histogram showing distribution of AFM 
volumes of all XPA proteins bound to ND538 (n = 161 particles) with Gaussian fit (solid black line). AFM volume 
corresponds to 26.7 ± 12.9 kDa, using the standard shown in Figure 7b. Dashed cyan line, Gaussian fit to the 
sub-fraction of non-specifically bound XPA (i.e. all internal complexes, n = 108); centered at 29.9 nm3 (s.d. 12.8 
nm3), corresponding to 28.0 ± 13.0 kDa. Dashed purple line, Gaussian fit to the sub-fraction of XPA bound at 
DNA ends (n = 53); centered at 25.5 nm3 (s.d. 11.7 nm3), corresponding to 24.1 ± 12.0 kDa. [d] Histogram 
showing the distribution of AFM volumes of all XPA proteins (n = 235 particles) bound to AAF538 with a 
Gaussian fit (solid black line). The AFM volume corresponds to 29.0 ± 13.1 kDa. Dashed red line, Gaussian fit 
to the sub-fraction of XPA bound between 20 and 40% of the DNA contour length (“specific,” n = 58); centered 
at 32.4 nm3 (s.d. 14.4 nm3), corresponding to 30.2 ± 14.4 kDa. Dashed cyan line, Gaussian fit to the sub-fraction 
of XPA bound internally but at positions away from the lesion (“non-specific,” n = 84); centered at 30.5 nm3 
(s.d. 11.4 nm3), corresponding to 28.5 ± 11.8 kDa. Dashed purple line, Gaussian fit to the sub-fraction of XPA 
bound at DNA ends (n = 51); centered at 28.3 nm3 (s.d. 13.0 nm3), corresponding to 26.6 ± 13.2 kDa. 
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3.4 XPA Bends DNA ~60° 
Having shown that XPA binds to damaged and non-damaged DNA as a monomer, we next 
asked whether XPA induces a bend at the dG-C8-AAF site. We first sought to determine if the 
dG-C8-AAF lesion itself introduces any flexibility into the DNA helix. Because this lesion was 
placed at 30% from the 3’ end of the AAF538 substrate, we measured the DNA bend angle at this 
site for unbound DNA. Note that while there is only a single lesion in our damaged substrate, we 
measured the angle at 30% from both ends (resulting in two angles per DNA molecule) because, 
under the current conditions, we are unable to differentiate between the 5’ and 3’ end of the 
molecule. As a negative control we measured the DNA angle at 30% from each end on the 538 bp 
non-damaged substrate, ND538 (Figure 11a), and found the majority of angles were around 0° 
(Figure 11c). The distribution for the dG-C8-AAF-modified DNA, AAF538, showed the emergence 
of a second population of bend angles (Figure 11b,d). A double Gaussian fit to the data describes 
two populations at 10.5 ± 7.0° and 34.8 ± 10.6°. While the smaller angle likely represents the 
unmodified site, the larger angle is likely the result of flexibility introduced by dG-C8-AAF165,166. 
We next sought to determine if XPA bends the DNA. By AFM, we see that XPA bends 
both non-damaged (Figure 11e) and AAF-adducted (Figure 11f) DNA. DNA angles were 
measured at all sites of internally-bound XPA. On ND538, XPA induced a bend angle of 54.0 ± 
30.1° (Figure 11g). On AAF538, XPA induced a bend angle of 58.6 ± 26.8°; the distribution was 
essentially the same for XPA bound near the lesion or non-specifically (Figure 11h). This angle is 
greater than that introduced by the lesion itself (~30°). Together, these data indicate that XPA 
binds preferentially to the helix-bending dG-C8-AAF and that, regardless of binding site, the 




Figure 11. dG-C8-AAF introduces DNA bending and XPA bends DNA ~60° when it binds. 
[a-b] Representative AFM image of free 538 bp non-damaged DNA (a, ND538) or free 538 bp DNA with a single 
dG-C8-AAF adduct at 30% from one end (b, AAF538). Color scale represents AFM height and applies to all 
panels. Dashed white line indicates the example in the cartoon below. Angles were measured at sites 30% of the 
total DNA contour length from each end and are reported as the θ angle (supplement to internal DNA angle). 
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[c] Histogram and Gaussian fitting of the inherent DNA bend angle of non-damaged DNA (n = 176 angles). [d] 
Histogram and double Gaussian fitting of the inherent DNA bend angle of AAF-adducted DNA (n = 106 angles). 
Each peak of the Gaussian is labeled as mean ± s.d. [e-f] Representative AFM image of XPA bound to ND538 (e) 
or AAF538 (f). The dashed white line indicates the example in the cartoon below. Angles were measured at sites 
of bound XPA and are reported as the θ angle. [g] Histogram showing the distribution of DNA bend angles at 
all sites of internally bound XPA on ND538 (n = 99 angles). [h] Histogram showing distribution of DNA bend 
angles at all sites of internally bound XPA on AAF538 (n = 181 angles) with Gaussian fit (solid black line). 
Gaussian is labeled as mean ± s.d. Dashed red line, Gaussian fit to the sub-fraction of angles at XPA sites 
between 20 and 40% of the DNA contour length (“specific,” n = 116); centered at 60.2° (s.d. 25.7°). Dashed cyan 
line, Gaussian fit to the sub-fraction of angles at sites of XPA bound internally but at positions away from the 
lesion (“non-specific,” n = 65); centered at 55.3° (s.d. 28.5°). 
3.5 XPA Performs Episodic One-Dimensional Diffusion to Search DNA for Damage 
The width of the Gaussian distribution of XPA binding position on AAF538 (i.e. observed 
non-specific binding around the dG-C8-AAF site) suggests that the protein might be dynamic on 
DNA. We have previously shown that Rad4-Rad23, which adopts a similar distribution of binding 
positions by AFM, performs constrained linear diffusion around a lesion22. Therefore, we next 
sought to investigate whether XPA displays one-dimensional diffusion on non-damaged and 
damaged DNA using a single molecule DNA tightrope assay138,140,142.  
DNA tightropes consisted of long (> 40 kbp) DNA molecules suspended between poly-L-
lysine-coated silica microspheres in a flow cell. To visualize XPA on these tightropes, the purified 
His-tagged protein was labeled with either a streptavidin-conjugated 705 nm quantum dot (Qdot) 
and biotinylated anti-His antibody (Figure 12a) or an anti-mouse IgG antibody-conjugated 605 nm 
Qdot and mouse anti-His antibody. Both labeling strategies resulted in similar observed behavior 
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(Figure 3e). For observation, flow was turned off and Qdots were excited with a 488 nm laser at 
an oblique angle (optimized to illuminate particles above the surface of the flow cell, in the plane 
of suspended DNA) and 300 second movies were recorded at 10-12 frames per second (fps) of 
XPA on one of three different tightrope substrates: non-damaged genomic λ DNA (NDλ), UV-
treated λ DNA (UVλ20J and UVλ80J), and defined arrays of dG-C8-AAF (AAFarray). We have 
previously determined that exposure of λ DNA to 20 J/m2 254 nm UV radiation results in a lesion 
density of approximately one UV photoproduct every 2.2 kbp21. Therefore, λ DNA was treated 
with 20 J/m2 or 80 J/m2 (producing 4X lesion density, or approximately one lesion every 550 bp) 
254 nm UV-C to generate UVλ20J and UVλ80J, respectively. Because UV-C radiation leads to 
formation of lesions comprising ~75% CPDs and ~25% 6-4PPs25, we expect UVλ80J to contain 
one 6-4PP every ~2.2 kbp. AAF arrays were prepared via end-to-end ligation of a 2030 bp 
fragment of linear DNA with a single site-specific dG-C8-AAF modification21,142. Kymographs 
were first categorized into four groups: stationary/persistent, stationary/dissociated, 
motile/persistent, and motile/dissociated. Motility was defined as linear displacement greater than 
130 nm (three pixels, see Section 2.6.4 Data Analysis) over the course of observation. XPA was 
primarily stationary (60-70% of the molecules) on all tightrope substrates (Figure 12b, flXPA). 
Although the proportions of these broad categories do not appear to be affected by the DNA 
substrate, we expected the nature of XPA’s motion to differ. Further detailed analyses of the motile 
fraction (i.e. those that moved at least once) are presented here and below.  
Unlike other repair proteins we have observed at the single molecule level21-23, it is 
interesting to note that the motile XPA particles often switched their behavior multiple times 
during observation (Figure 12c). Most exhibited some periods of pausing between episodic phases 
of linear diffusion. To analyze these differences, we categorized the behavior of motile XPA into 
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three distinct modes: paused (particle not moving), short-range diffusion (displacement less than 
690 nm), and long-range diffusion (displacement greater than 690 nm). Thresholds for motile 
modes were chosen based on approximate distances between lesions; assuming true B-form DNA, 
2,030 bp corresponds to 690 nm. Figure 12c shows an example of XPA on NDλ, exhibiting all 





Figure 12. XPA exhibits episodic linear diffusion on DNA tightropes. DNA damage leads to increased 
pausing, dependent on N- and C-termini. 
[a] Cartoon showing one strategy used for XPA labeling on DNA tightropes. His-tagged XPA is labeled with a 
biotinylated anti-His antibody bound to a streptavidin-conjugated 705 nm quantum dot. See Section 2.6.2 for 
alternative labeling strategy. [b] Stacked bar graph showing the fraction of motile (teal) vs. stationary (white) 
and persistent (solid) vs. dissociating (diagonal lines) particles of full-length XPA (flXPA) on non-damaged λ 
(NDλ, n = 124 particles), 20 J/m2 UV-irradiated λ (UVλ20J, n = 147), 80 J/m2 UV-irradiated λ (UVλ80J, n = 54), 
and AAF arrays (AAFarray, n = 45), and of truncated XPA (truncXPA) on UVλ80J (n = 63). Motile particles are 
defined as those which moved more than 130 nm on DNA during 300 s observation. ns, no significant difference 
between groups by χ2 for all flXPA experiments, for all flXPA and truncXPA categories, or for truncXPA on 
UVλ80J vs. flXPA on UVλ80J. [c] Example of a motile kymograph (cut to show only 80 s of the recorded movie) 
of 705 nm quantum dot-labeled XPA on NDλ. Particle position (bottom) was localized using Gaussian fittings 
to the intensity profile on the fluorescence image (top). Dashed lines separate phases and diffusive modes are 
labeled according to particle displacement: paused (P, displacement < 130 nm, tan), short-range motion (S, 
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displacement 130 – 690 nm, navy), and long-range motion (L, displacement > 690 nm, lavender). Arrows point 
to pause sites occupied by particle. [d] Stacked bar graph showing the fraction of time spent in each mode as 
percentage of total time recorded for all motile particles. ****, p < 0.0001 by χ2 for all flXPA experiments and 
for truncXPA on UVλ80J vs. flXPA on UVλ80J. [e] Histogram of number of pause sites for flXPA on NDλ (n = 
31 particles), UVλ20J (n = 46), and UVλ80J (n = 16), and for truncXPA on UVλ80J (n = 24). 
3.6 Presence of DNA Damage Increases Pausing in Motile XPA Particles 
Notably, the presence of damage in the DNA tightrope had an impact on the occupancy of 
each mode. The proportion of seconds spent in each mode was calculated as a fraction of total 
recorded time for motile particles (Figure 12d). Full-length XPA (flXPA) demonstrated a clear 
dose-dependent increase in paused time with increasing damage. Motile particles of flXPA spent 
52% of the time paused on NDλ tightropes; this increased to 56% on UVλ20J, 67% on UVλ80J, and 
71% on AAFarray, and was accompanied by a decrease in time spent in the diffusive modes, 
especially long-range mode. 
Another unique feature of XPA linear diffusion on DNA was that the protein appeared to 
prefer and return to certain positions on the tightropes. These positions, deemed “pause sites,” 
were defined as sites at which XPA spent at least one paused phase (at least five seconds), and 
were examined as a second measure of particle pausing. On NDλ, the majority of XPA particles 
(48.4%) paused at just one position (Figure 12e, top row). On UVλ20J, the majority of XPA 
particles (39.1%) paused at two distinct positions (Figure 12e, second row), and on UVλ80J, the 
majority (25.0%) occupied three distinct positions, with some occupying as many as 10 positions 
(Figure 12e, third row). The increasing number of pause sites observed with increasing UV lesion 
density in the tightropes strongly suggest that these positions correspond to sites of damage. Pause 
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sites observed on non-damaged DNA might represent other distorted regions of the DNA (e.g. A-
tract-GC junctions or spontaneous damage sites). Future work will be necessary to confirm the 
nature of these pause sites. Due to the small sample size of motile XPA particles on AAFarray (n=6), 
this dataset was not included in this and subsequent analyses. 
3.7 Truncated XPA Exhibits Reduced Pausing on Damaged DNA 
We next examined the behavior of a truncated XPA mutant (His-truncXPA-StrepII, or 
truncXPA) to investigate the conformation of XPA during linear diffusion and pausing. We 
hypothesized that the intrinsically disordered N- and C-terminal arms of XPA play a role during 
target search. Thus, the N- and C-termini were deleted, leaving only the currently accepted DNA-
binding domain, M98 through T239 (ref. 77). truncXPA maintains its ability to bind non-damaged 
37 bp DNA (KD = 268.8 ± 22.3 nM) with similar affinity as flXPA (Figure 4e). Specific binding 
of truncXPA to an AAF adduct (KD = 188.6 ± 8.9 nM) is only ~53-fold (Figure 4g). Thus, we 
observed a reduction in specificity to dG-C8-AAF by a factor of 1.6 in the truncated XPA 
compared to full-length. All specificity was lost for CPD (KD = 269.2 ± 24.4 nM, Figure 4i). 
We turned to our DNA tightrope platform to test truncXPA target search on UVλ80J 
tightropes. Statistically, truncXPA exhibited the same proportion of stationary/motile and 
persistent/dissociated particles as flXPA (Figure 12b). Importantly, for motile particles, we 
observed a significant decrease (~25%) in time spent paused and a corresponding increase in time 
spent undergoing long-range motion for truncXPA compared to flXPA on UVλ80J (Figure 12d). 
Furthermore, the number of pause sites occupied by truncXPA  on UVλ80J (37.5% of particles had 
only two pause sites) was dramatically less than the number of pause sites occupied by flXPA on 
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UVλ80J (Figure 12e). By these measures, truncXPA behavior on UV-irradiated DNA more closely 
resembled flXPA behavior on non-damaged DNA. Together with the biochemical assays, these 
data suggest that while the core DNA-binding domain of XPA is capable of recognizing damage 
and forming stationary complexes, its ability to transition into the paused state and form high 
affinity stable complexes is sharply impaired without the N- and C-termini. 
3.8 XPA Changes Search Mode on the Second Time Scale 
We then considered the lengths of all individual phases to obtain an estimate for the 
lifetimes of motile XPA particles in each mode. Although multiple comparisons resulted in 
statistically significant differences between some experimental groups, the majority were not 
significant and there appears to be no meaningful trend between substrates or XPA length (Figure 
14a). Therefore, analysis was done on the combination of all flXPA data (Figure 13a). A single 
exponential was fit to the cumulative frequency distribution of phase lengths for each mode. The 
resulting mean lifetimes (τ) are as follows: 33.0 s for paused phases, 17.4 s for short-range phases, 
and 13.5 s for long-range phases. These data suggest that paused phases tend to last longer than 
phases of either diffusive mode. Moreover, within the defined limits of experimental temporal 
resolution, XPA changes its search state on the second time scale. We must also note the significant 
proportion of XPA particles that were stationary (i.e. did not move once during 300 second periods 





Figure 13. Short-range motion is associated with a lower diffusion coefficient. 
[a] Cumulative frequency distributions of the lengths of paused (n = 638 phases), short-range (n = 665 phases), 
and long-range (n = 119 phases) phases for flXPA on combined λ substrates (NDλ, UVλ20J, and UVλ80J). A single 
exponential (curved line) is fit to each histogram (circles) and resulting k is reported as best fit value ± s.e. of 
the fit. Mean lifetime, τ = 1/k. [b] Box and whisker plot (5-95 percentile) of the diffusion coefficient (log10D) 
calculated for short-range (n = 505 phases) and long-range (n = 79 phases) phases of Qdot-flXPA on combined 
λ substrates (NDλ, UVλ20J, and UVλ80J). +, sample mean. Dashed line, Dlim, theoretical limit to free diffusion for 
Qdot-flXPA. **** p < 0.0001 by two-tailed Student’s t test. [c] Plot of diffusion coefficient (D) vs. length of 




Figure 14. Comparison of phase lengths and diffusion coefficients between experiments. 
[a] Box and whisker plots (5-95 percentile) of the lengths (in seconds) of all measured phases for motile XPA 
particles. Left, paused mode: flXPA on NDλ (n = 193 phases), flXPA on UVλ20J (n = 239 phases), flXPA on 
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UVλ80J (n = 157 phases), truncXPA on UVλ80J (n = 136 phases). Center, short-range mode: flXPA on NDλ (n = 
214 phases), flXPA on UVλ20J (n = 254 phases), flXPA on UVλ80J (n = 150 phases), truncXPA on UVλ80J (n = 
154 phases). Right, long-range mode: flXPA on NDλ (n = 55 phases), flXPA on UVλ20J (n = 27 phases), flXPA 
on UVλ80J (n = 10 phases), truncXPA on UVλ80J (n = 27 phases). All comparisons within each mode by Dunn’s 
multiple comparisons test were not significant (p > 0.05) except for: paused flXPA/NDλ vs. flXPA/UVλ20J (p = 
0.0025), short-range flXPA/NDλ vs. flXPA/UVλ80J (p = 0.0005), short-range flXPA/UVλ20J vs. flXPA/UVλ80J (p 
< 0.0001), and short-range flXPA/UVλ80J vs. truncXPA/UVλ80J (p < 0.0001). Data reproduced from Figure 13a, 
but separated to show variation between experimental conditions. [b] Box and whisker plots (5-95 percentile) 
of D of all analyzed phases. Center, short-range mode: flXPA on NDλ (n = 156 phases), flXPA on UVλ20J (n = 
211 phases), flXPA on UVλ80J (n = 138 phases), truncXPA on UVλ80J (n = 131 phases). Right, long-range mode: 
flXPA on NDλ (n = 49 phases), flXPA on UVλ20J (n = 20 phases), flXPA on UVλ80J (n = 10 phases), truncXPA 
on UVλ80J (n = 22 phases). All comparisons within each mode by Dunn’s multiple comparisons test were not 
significant (p > 0.05) except for: short-range flXPA/NDλ vs. flXPA/UVλ20J (p < 0.0001) and short-range 
flXPA/UVλ20J vs. flXPA/UVλ80J (p < 0.0001). Data reproduced from Figure 13b, but separated to show variation 
between experimental conditions. [c] Plots of diffusion coefficient (D) vs. length of phase. flXPA on NDλ, n = 
205 phases. flXPA on UVλ20J, n = 231 phases. flXPA on UVλ80J, n = 148 phases. truncXPA on UVλ80J, n = 153 
phases. Data reproduced from Figure 13c, but separated to show variation between experimental conditions. 
3.9 Long-Range Motion is Associated with Faster Rates of Diffusion than Short-Range 
Motion 
In order to gain insight into the rates of diffusion, we used mean squared displacement 
(MSD) analysis142,167. Because motile XPA changed its behavior so distinctly, generating MSD 
plots for the entire length of each kymograph was not appropriate. Instead, each diffusive phase 
(short- and long-range) was analyzed independently. We first combined the motions of full-length 
XPA particles on all substrates in order to compare diffusion between modes. The diffusion 
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coefficient (D) is an order of magnitude lower in the short-range mode (D ≈ 3.2 × 10-3 μm2/s) 
compared to long-range (D ≈ 3.7 × 10-2 μm2/s), implying that the rate of displacement is slowest 
when the protein is traveling shorter distances overall (Figure 13b). Interestingly, we also observed 
that there is a correlation between phase length and diffusion coefficient, with the fastest diffusing 
particles having the shortest time spent in that phase (Figure 13c). There was no meaningful 
difference between diffusion rates on all substrates for flXPA or truncXPA (Figure 14b); while 
some differences were noted between experimental groups, there was no meaningful trend, and all 
plots of D against phase length resulted in a similar shaped distribution (Figure 14c). This suggests 
that diffusion rates are inherent to the mode of diffusion itself. Together, these data indicate that 
while XPA’s entry into a paused state is dependent upon the disordered N- and C-terminal 
domains, phase lengths and diffusion rates are dictated by the core DBD. 
The calculated theoretical limit to the diffusion coefficient for Qdot-XPA corkscrewing 
along the DNA helix (Dlim) is 0.015 μm
2/s (see Section 2.6.5 Calculation of Theoretical Constants, 
Equation 9) and appears to separate the short-range from the long-range mode (Figure 13b-c). This 
limit was calculated with the assumption that Qdot-labeled XPA is sliding on the DNA, 
maintaining contact and following the helical path153. The fact that a significant portion of the 
long-range phases exceed this limit suggests that, when in this mode, XPA is undergoing an 
alternative mechanism of linear diffusion, namely hopping. To reconcile this, we compared the 
behavior of full-length XPA on UVλ20J and UVλ80J tightropes in buffers with different ionic 
strengths. Proteins that are hopping along the DNA are expected to exhibit faster diffusion in 
higher salt concentrations, while those that are truly sliding on DNA are expected to be relatively 
unaffected by changes in salt1. Comparing the maximum displacement of XPA, we observed a 
significant correlation between salt concentration and range of motion (Figure 15a). Diffusion 
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coefficients for XPA undergoing short-range diffusion at higher salt all fall within the range 
observed at 100 mM KCl (Figure 15b), thus supporting the sliding model. However, consistent 
with the hopping model, increased salt concentration resulted in an increase in the diffusion 
coefficient for XPA undergoing long-range motion. 
 
 
Figure 15. Effect of ionic strength on XPA diffusion. 
[a] Box and whisker plot (5-95 percentile) showing maximum displacement of motile XPA particles on UVλ20J 
and UVλ80J with buffer containing 100 mM (n = 61), 150 mM (n = 11), or 1 M salt (n = 4). , sample mean. ** 
p = 0.0.0045 by Post test for linear trend. [b] Plot of the log transform of diffusion coefficient (D) of motile XPA 
on UVλ20J and UVλ80J with buffer containing 100 mM KCl, 150 mM NaCl, or 1 M NaCl. The 100 mM data are 
reproduced from Figure 13c (UVλ20J and UVλ80J only, subset of total), shown for comparison. Circles show 
individual data points, bars show means. ns, p = 0.5613; **, p = 0.0051 by Post test for linear trend. [c] Example 
kymograph of XPA on UVλ20J. Starting buffer contains 100 mM KCl. The arrow indicates the transition from 
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4.1 Working Model 
In this study we have pursued a collection of single molecule experiments that uniquely 
address several questions about how XPA interacts with DNA. AFM data indicate that full-length 
human XPA has specificity for the helix-bending dG-C8-AAF lesion and that it binds and bends 
both damaged and non-damaged DNA as a monomer. Single molecule fluorescence microscopy 
showed that XPA is primarily stationary when bound to DNA. Of the proteins that did move, the 
presence of DNA damage increased pausing in a dose-dependent manner. A truncated XPA mutant 
consisting of just the core DNA-binding domain displayed impaired pausing compared to full-
length on damaged DNA tightropes. MSD analysis revealed that the short-range mode had a 
significantly lower diffusion coefficient than the long-range mode, which exceeded the theoretical 
limit for protein sliding along the DNA contour. Our working model for XPA damage search and 
recognition is presented in Figure 16. 
4.1.1  Stoichiometry 
Although XPA has been reported to bind DNA as a homodimer on short DNA substrates90, 
volumes of XPA (at concentrations between 1 and 4 μM) on a 538 bp DNA substrate measured by 
AFM in this study are consistent with the size of a monomer. We also observed formation of a 
“dimer band” at high concentrations by EMSA, but this band is indistinguishable from a complex 
containing one XPA bound at the lesion and one bound at the DNA end (or two otherwise distinct 
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monomeric binding events). Indeed, our AFM data show that a significant fraction of XPA was 
bound to ends of the DNA molecule in addition to specific sites. Previous work has addressed the 
issue of end-binding by performing protein-protein crosslinking experiments of Rad14 DBD on 
15 or 37 bp AAF-adducted DNA85. Dimers observed in this study may be a unique property of 
Rad14, the truncated protein, or, as the authors state, due to unusual bending of the DNA. 
Furthermore, Rad14 concentrations in structural and crosslinking studies were very high (in mM 
amounts, compared to the μM concentrations used in the present study), as required by the 
protocol. As such, AFM imaging of full-length human XPA on long DNA substrates has allowed 
us to gain new insight into XPA binding stoichiometry. The monomeric state of free XPA observed 
at 40 nM by AFM and up to 80 μM by MALS provides further evidence against a dimer interface. 
4.1.2  DNA Bending and Specificity 
The addition of a dG-C8-AAF base modification to our AFM DNA substrate resulted in 
increased flexibility and a ~30° bend at that site, consistent with previous reports that an AAF 
modification distorts B-form DNA165,166. Furthermore, XPA was shown to bend both damaged and 
non-damaged DNA by ~60°. Extensive reports in the literature suggest that XPA binds 
preferentially to a distorted DNA helix46,48,55,60,76,79,85,86,91,93-99,101-103,110, and our current work 
supports the hypothesis that XPA interrogates DNA by bending and testing for flexibility or pre-
bent structures. The energy required to bend DNA at an AAF site is expected to be less than at a 
non-damaged site32,85, and thus XPA may preferentially fold into a stable complex more readily at 
this and other DNA lesions. 
We observed preferential XPA binding to dG-C8-AAF with a specificity factor of 660, 
which is in the range of reported specificities of Taq MutS for its substrates, a T-bulge and G:T 
71 
mismatch (1,660 and 300, respectively)149. Interestingly, XPA had a similar distribution of binding 
positions (standard deviation of the Gaussian fit was 12.3 % of the total DNA contour length) as 
we have previously observed for Rad4-Rad23 on a fluorescein-adducted substrate (standard 
deviation was 13% of the total DNA contour length)22. While the specificity factors determined 
by EMSA and AFM cannot be directly compared, in support of the AFM data, the specificity of 
XPA for dG-C8-AAF compared to non-damaged DNA by EMSA was ~85-fold. These levels of 
specificity support the “discrimination cascade” model for damage recognition in NER58-60. 
One limitation of the single molecule methods presented in this dissertation is that, by 
nature of the method, only relatively stable complexes can be detected. Extremely transient or 
weak binding events may not be recorded (e.g. appear as free unbound molecules by AFM, or 
never be discovered when searching for bound particles along DNA tightropes) and thus we are 
artificially filtering our protein population for the “best” binders. This makes it difficult to assess 
protein affinity or specificity for DNA targets using these methods alone. However, additional 
information resulting from bulk biochemical work and comparison with other well-studied 
proteins allows one to obtain a more complete picture of the protein-DNA interaction of interest. 
4.1.3  Episodic Linear Diffusion 
The role of linear diffusion in target search was explored further via the DNA tightrope 
assay. The episodic behavior of XPA appears to be a relatively unique property for DNA binding 
proteins, as few other single-particle tracking studies have yielded similar results, save for a recent 
report on the SA1 protein sliding on telomeric DNA tightropes168. It appears that XPA cycles 
through three distinct states on DNA: rapidly diffusing over distances greater than 2.2 kbp (690 
nm), slowly diffusing and more carefully interrogating short (< 2.2 kbp) ranges of DNA, and 
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binding stably in a long-lived non-motile complex. Our data indicate that switching between 
modes is not dependent on the DNA substrate, but more likely occurs stochastically on the second 
time scale. These three states, combined with the AFM data, support a working model in which 
monomeric XPA interacts with DNA by quickly sampling large stretches of DNA by hopping, 
slowly interrogating and bending smaller regions as it slides along the DNA contour, and forming 
high-affinity complexes with sharply bent DNA (Figure 16). DNA with a high propensity for 
bending, such as at a dG-C8-AAF adduct165,166 or 6-4PP27, promotes formation of these stable 
complexes.  
These states are reminiscent of the two-state model proposed by Slutsky and Mirny 
(discussed in Section 1.1)5. In response to the speed-stability paradox of protein-DNA target 
search, the authors suggest that proteins adopt two conformations: a search state with a smooth 
DNA-binding energy landscape, allowing for rapid search, and a recognition state with a rugged 
energy landscape. Comparably, linear diffusion observed by XPA fits this model. Paused and 
stationary particles conform to a recognition state with exceedingly rough binding energy 
landscapes while short- and long-range diffusing particles correspond to distinct subgroups (and 
thus distinct energy landscapes) within a search state. 
The energy barrier to free diffusion (σ = 1.6 × kBT, see Section 2.6.5 Calculation of 
Theoretical Constants) in the short-range mode (i.e. displacement less than 690 nm or ~2.2 kbp) is 
essentially identical to that reported for Rad4-Rad23 undergoing constrained motion22. We 
attribute the slower rate of diffusion observed in the short-range mode to two factors. First, as XPA 
bends DNA to assess damage/helical distortions, this likely induces propagation of the bend along 
the DNA molecule, thereby increasing roughness of the energy landscape and ultimately limiting 
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diffusion169. Second, we report that XPA in this mode is translocating along the DNA by spiraling 
in constant contact with the helix. 
Diffusion coefficients determined for XPA in the long-range mode, however, exceeded the 
theoretical limit of the diffusion coefficient for XPA sliding in this manner (and consequently, we 
are unable to calculate corresponding energy barriers to diffusion). Therefore, it is possible that 
XPA is hopping (i.e. rapidly undergoing micro-associations and dissociations from the DNA) in 
order to achieve the faster diffusion observed in the long-range mode. This model is further 
supported by the fact that increasing ionic strength of the buffer resulted in higher diffusion 
coefficients for long-range phases, presumably due to an increased distance of each “hop.” The 
failure of increasing salt concentrations to have this effect on short-range phases again supports a 
sliding model, in which XPA is spiraling and maintaining contact with the DNA. In the cell, a 
search mechanism involving hopping would have the advantage of the protein being able to move 
along the DNA without being stopped by other protein-DNA complexes or nucleosomes. 
4.1.4  XPA DNA-Binding Domain 
We next hypothesized that the intrinsically disordered N- and C-termini of XPA play a role 
in DNA bending and pausing. Here we show that truncated XPA, consisting of just residues 98-
239 of the core DNA-binding domain, maintains its ability to adopt a recognition state on damaged 
DNA. No differences were observed in phase lengths or diffusion coefficients between the 
truncated and full-length proteins. The number of stationary particles (i.e. long-lived non-motile 
complexes) and the lengths of each paused phase were statistically non-distinct between truncXPA 
and flXPA on UV-damaged DNA tightropes, indicating that both proteins are able to form stable 
complexes on DNA and that once this complex is formed, the N- and C-terminal arms are not 
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involved in switching modes out of the paused state. However, motile particles of truncated XPA 
were significantly impaired in their ability to pause on damaged DNA, as demonstrated by a 
decreased number of pause sites as well as decreased total time spent in the paused mode (as a 
result of a lower frequency of paused phases). Therefore, the N- and C-terminal arms likely do 
play a role in finding the lesion and may serve as metaphorical brakes, allowing XPA to slow down 
and test the DNA for a lesion. This is further supported by EMSA results showing that truncXPA 
binds non-damaged DNA with similar affinity as flXPA, but has approximately half of the 
specificity for an AAF adduct. These data are consistent with a model in which the core DNA-
binding domain is able to form stable complexes, but the disordered arms play a role in embracing 
the DNA and interrogating for helix-distorting damage, inducing a conformational change to 
stabilize pausing. 
An important study by Chazin and colleagues concluded that residues 98-239 of XPA were 
sufficient to achieve wild type DNA-binding77. They demonstrated that truncated XPA, containing 
just these residues, bound dsDNA, ssDNA, and a Y-shaped ss/dsDNA junction with similar 
affinity as full-length XPA. It is important to note that DNA duplexes representing initial  NER 
substrates/lesions were not tested. As previously reported, we observed similar affinity between 
truncXPA and flXPA for non-damaged dsDNA. However, we show that residues 98-239 were not 
sufficient to achieve wild-type binding to an AAF-adduct. This distinction suggests that perhaps 
the N- and C- termini are not required for XPA to bind the Y-shaped substrate77, but they do play 
a role in recognizing and stopping at a lesion. This is consistent with a model in which the 
disordered arms of the protein are involved in the early steps of damage recognition. Then, as NER 
proceeds and XPA must bind to intermediate DNA structures and act as a scaffold protein, the 
arms change function and interact with other proteins rather than DNA. 
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Along these lines, given the many reported interactions between XPA and other NER 
proteins54,58, we cannot ignore the possibility that XPA behaves differently in the presence of other 
repair partners. As such, we present our model as a starting point, illustrating XPA DNA binding 
behavior and diffusive properties in isolation, with further studies required to investigate the role 




Figure 16. Working model of XPA linear diffusion on DNA. 
Fast search (long-range linear diffusion): monomeric XPA translocates rapidly by hopping (micro-
associations/dissociations) along the DNA backbone. The protein’s disorder and lack of contacts with DNA 
permit rapid diffusion (D ≈ 0.04 μm2/s). Bend propagation (short-range linear diffusion): XPA follows the path 
of the major or minor groove, spiraling along DNA (D ≈ 0.003 μm2/s). The N- and C-termini of the protein may 
be partially folded, making more contacts with the DNA. The protein bends DNA, testing for 
flexibility/aberrations, and propagation of the bend further slows diffusion. Recognition complex (paused and 
stationary particles): the disordered ends of the protein fold into a stable complex, bending the DNA ~60°. The 
NMR structure of the XPA DNA-binding domain (PDB 1XPA) was used in combination with an estimation for 
the N- and C-termini (disorder represented by size/transparency) as an approximate model to display the 
complete XPA molecule. 
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4.2 Outlook 
The single molecule studies of XPA on DNA presented here resolve several important 
questions about its damage recognition behavior (as discussed in Section 4.1). However, in the 
everlasting cycle of scientific research, these studies have perhaps opened more questions than 
they have answered. 
4.2.1  XPA Specificity 
As laid out in Appendix B, Table 1, and discussed in Section 1.3.2 (XPA-DNA 
Interactions), there have been numerous studies investigating XPA specificity for a wide range of 
DNA substrates. However, none have done a side-by-side comparison with a truly helix-bending 
lesion in dsDNA and forked NER-intermediate mimics. There is much debate and conflicting 
conclusions in the literature regarding XPA’s role in damage recognition. The “early XPA” 
supporters tend to cite literature showing XPA has specificity for DNA lesions while “late XPA” 
supporters give more weight to literature examining forked substrates, and it is significantly 
difficult to compare results between papers. The common theme with all these studies is that XPA 
binds flexible DNA preferentially over dsDNA. If these studies are going to be used to support 
one model vs. another, then perhaps one way to resolve some of the conflicting reports would be 
to do an extensive and comprehensive comparison study of full-length XPA binding to a wide 
range of DNA substrates, including multiple bulky adducts, crosslinks, and ss/dsDNA junctions. 
Sequential assembly of NER proteins has also been studied in cells by immunofluorescence 
(IF). Vermeulen and colleagues showed that XPA is required to recruit ERCC1 to UV-damaged 
foci, but not XPC, TFIIH, or XPG47. Such studies are more technically challenging to study 
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recruitment to chemical base damage like dG-C8-AAF. Furthermore, although the evidence 
demonstrates that XPA may not be required for recruitment of all downstream proteins, it does not 
negate the possibility that XPA may enhance damage recognition efficiency or that its interaction 
with DNA lesions is important for damage verification. Single molecule tracking of XPA and other 
recognition proteins (UV-DDB or XPC) in living cells would provide insight into complex 
formation in real time. 
4.2.2  Role of DNA Bending in XPA Damage Recognition 
Results of AFM experiments with XPA binding to dsDNA with or without an AAF adduct 
indicate that DNA bending plays an important role in recognition and target search. Currently, we 
have only examined DNA bending using our AFM platform, which provides a static snapshot of 
molecular conformations. We would like to resolve four additional questions stemming from these 
results. 
First, does XPA bind preferentially to DNA already in a sharply (60°) bent state (i.e. 
conformational capture) or does it induce conformational change of the DNA upon binding? AFM 
imaging of free DNA molecules with or without the AAF adduct indicate that the majority of 
molecules do not adopt a bend angle greater than 34° or 10°, respectively. However, as can be seen 
in Figure 11, a small number of unbound DNA molecules had a bend greater than 60°. Is XPA 
finding these pre-bent structures or does the DNA bend after binding? This is a subtle distinction, 
but the use of time lapse or high-speed AFM, which allows for greater temporal resolution, may 
allow one to observe protein-induced DNA bending, should it occur. Because XPA has an 
established propensity to bind DNA lesions which are both bent and flexible, I hypothesize that 
XPA does bind preferentially to bent structures, but with an additional component of induced fit, 
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resulting in a sharply bent structure. Along these lines, a parallel idea for damage recognition by 
UV-DDB, namely conformational proofreading, has been proposed21. The FQH hairpin of DDB2 
probes the major groove of the DNA molecule for damage and encounter with an appropriate 
lesion induces conformational changes in both protein (formation of an α paddle) and DNA (base 
flipping)21,170. 
Second, does XPA have any specificity for other non-damage associated bends in DNA? 
While numerous studies have examined XPA binding to a range of artificially distorted DNA 
substrates (see Section 1.3.2 and Appendix B), none have looked at bends caused by A-tract:GC 
junctions in dsDNA. We could test this first by EMSA, but perhaps more effectively by AFM. By 
measuring the XPA binding position on a 538 bp dsDNA fragment with this specific sequence at 
30% from one end would reveal any preferential binding. Affinity for sequence-induced DNA 
bending may also help to understand XPA pausing on non-damaged DNA tightropes (see below, 
Section 4.2.3 XPA Specificity on Non-Damaged DNA). 
Third, how does DNA tension and range of bending impact XPA diffusion on DNA 
tightropes? Under the current experimental set-up, DNA tightropes are suspended at 90% the total 
contour length of the DNA. These conditions should allow for localized DNA bending and have 
been demonstrably acceptable for the study of a number of DNA-binding proteins21,23, including 
those that bend DNA22. However, it is possible that reducing DNA tension even further may allow 
DNA bending more readily, and thus enhance XPA binding. To test this using our DNA tightrope 
platform, we would string up DNA under slower flow to allow for gentler elongation of DNA 
molecules. Investigating XPA diffusion on DNA tightropes at 80% or 70% contour length may 
reveal increased pausing. One limitation of this kind of experiment is that, if DNA tightropes are 
given too much slack, they will not remain within one plane (XY or Z) and will constantly move 
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in and out of focus when imaging. An alternative approach using optical tweezers may avoid this 
problem. In this kind of experiment, optical tweezers would first trap a DNA molecule at both 
ends, and then XPA would bind the DNA, and finally the tweezers would be manipulated to bring 
the ends of the molecule closer or further apart. By combining optical tweezers with fluorescence 
microscopy, use of the C-Trap™ (Lumicks) with labeled XPA would allow for direct visualization 
of this in real time. If our hypothesis that XPA must bend the DNA in order to form a stable 
complex is correct, we expect XPA to dissociate from DNA molecules as the ends are stretched 
further apart. 
Fourth, can the truncated XPA mutant bend DNA? Our single molecule tightrope 
experiments showed that, without its disordered N- and C-termini, XPA exhibits reduced pausing 
on damaged DNA. When it does pause, it stays paused for the same length of time as full-length 
XPA. If DNA bending is essential for specificity and pausing by XPA, then I predict that the 
truncated mutant will show impaired DNA bending. We can use AFM to measure DNA bend 
angles at sites of bound truncXPA on both the non-damaged and AAF-adducted substrates. The 
full-length XPA protein bent DNA ~60° at both non-specific and specific sites. If the N- and C-
terminal arms are necessary for DNA bending, we should see a smaller bend angle or perhaps a 
wider distribution of angles. 
4.2.3  XPA Specificity on Non-Damaged DNA 
Analysis of the number of pause sites occupied by XPA on various DNA tightropes 
indicated that XPA tends to pause at UV-induced lesions. In addition to this, we also observed 
XPA pausing on NDλ tightropes. What is the nature of the pause sites on NDλ? 
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To answer this, chromatin immunoprecipitation (ChIP) of different DNA samples may 
show XPA binding preferentially to certain genomic sequences. Specifically, as tightrope assays 
were performed using λ DNA, it is of most interest to determine if XPA is enriched at any particular 
regions of this substrate. Purified XPA (full-length, with a His tag) would be incubated with and 
crosslinked to λ DNA, the DNA would be fragmented, and XPA-DNA complexes would be 
immunoprecipitated using beads with anti-His antibodies attached. Adapter ligation may be used 
to build a library of DNA fragments for sequencing. The benefit of this assay is that it makes no 
assumptions about what XPA is seeing when it binds. 
However, because we do have additional data to inform our hypotheses, we can also begin 
to make some assumptions. As discussed above (Section 4.2.2 Role of DNA Bending in XPA 
Damage Recognition), XPA may be pausing at sequence-induced DNA bends. Alternatively, XPA 
may be pausing at spontaneous damage (most likely nicks in the DNA backbone or oxidized 
bases). ChIP sequencing results may also indicate other preferred sequences. Biochemical (EMSA 
or otherwise) assays in combination with AFM may be used to determine XPA specificity for such 
sequences and/or lesions to support ChIP sequencing results. 
Finally, these alternative specific binding sites for XPA may be tested using the DNA 
tightrope assay. Using NDλ DNA tightropes, DNA sequences, in close proximity to the predicted 
pause site, may be labeled with a biotinylated oligonucleotide, which can form a DNA triplex and 
subsequently be labeled with a streptavidin-coated Qdot. If the predicted sequences are true XPA 
pause sites, then colocalization should be observed between the labeled DNA and XPA, labeled 
orthogonally with a different color Qdot. Alternatively, arrays of plasmids with short sequences 
representing the predicted pause site and a proximal biotinylated base can be prepared as described 
(Appendix F). Colocalization would be observed in the same way. In the proposed experiment, 
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XPA may have limited range of linear diffusion if the DNA label serves as a roadblock to sliding 
(although XPA undergoing hopping would be expected to bypass the triplex DNA). Therefore, 
controls must be performed with DNA labeled at a “neutral” site to test if XPA will pause at the 
label, regardless of DNA sequence. 
4.2.4  XPA Interaction with Other NER Proteins 
As discussed in Section 1.3.3 (XPA-Protein Interactions), XPA is an important scaffold 
protein for NER. The studies presented in this dissertation, using purified XPA and DNA in 
isolation, were necessary to gain a fundamental understanding for DNA damage search by XPA. 
They also provide the groundwork for subsequent studies with additional proteins. Ultimately, we 
would like to fully reconstitute mammalian NER at the single molecule level. 
To this end, the next steps, with respect to XPA, would be to examine how XPA interaction 
with damaged DNA is altered in the presence of partner proteins. Specifically, UV-DDB52 and 
RPA55 have both been reported to enhance binding affinity of XPA for damaged DNA. Therefore, 
I predict that addition of these proteins to enhance damage search by XPA. Using orthogonally-
labeled proteins on our DNA tightrope platform, one could look for colocalization of XPA with 
UV-DDB or RPA on DNA. Furthermore, any impact on diffusion, such as increased frequency of 
stationary particles or pausing within the motile fraction, could be observed as a synergistic target 
search. AFM could also be used to observe formation of ternary complexes on DNA. 
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4.2.5  XPA Damage Search in Chromatin 
One last set of experiments (though certainly not the requisite end of this story) would 
investigate the effects of chromatin structure on damage search by XPA. The use of long DNA 
substrates in our tightrope assay is arguably a more biologically relevant substrate compared to the 
short oligonucleotides often used in biochemical assays. However, DNA in human nuclei is 
wrapped in nucleosomes and condensed into chromatin. Histone proteins may thus act as 
roadblocks or physical barriers to XPA sliding along DNA. Finkelstein and colleagues recently 
used a single molecule tracking platform (DNA curtains171-173) to show that the yeast mismatch 
repair proteins Msh2-Msh3 primarily search DNA for damage via a hopping mechanism, and thus 
are able to bypass nucleosomes during target search174. Conversely, they found that Msh2-Msh6 
performs target search via sliding, and cannot hop over nucleosomes174. 
In this manner, by adding nucleosomes to our DNA tightrope platform, we can investigate 
XPA diffusion in the context of chromatin. The ability of XPA to perform facilitated diffusion by 
alternating between sliding and hopping may allow for the protein to bypass nucleosomes when 
undergoing long-range diffusion, but not short-range. Thus, we would expect to see particles 
undergoing long-range diffusion to continue past such roadblocks. The range of displacement for 
particles undergoing short-range diffusion would be limited by the spacing between nucleosomes. 
4.3 Concluding Remarks 
In this dissertation, we present a thorough single molecule analysis of XPA DNA damage 
recognition. Taken together, our data is consistent with a three-state model for DNA target search 
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(Figure 16). The “search state” of XPA can be broken down into two modes. Fast search 
corresponds to a conformation which allows for rapid sampling over long (> 690 nm) distances of 
DNA, which involves DNA hopping. Slow search corresponds to a conformation with slower 
linear diffusion via sliding over short distances. In this mode, we predict XPA to bend DNA and 
test for flexibility. The “recognition state” of XPA occurs when the DNA helix is bent by ~60°. 
The intrinsically disordered N- and C-termini of the protein embrace the DNA and facilitate 
pausing and formation of the recognition state. 
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Appendix A Abbreviations 
λ – Enterobacteria phage lambda 
6-4PP – (6-4) pyrimidine-pyrimidone photoproduct 
AF – 2-aminofluorene 
AAF – 2-acetylaminofluorene 
AAN – N2-acetylnaphthyl 
AFM – Atomic force microscopy 
AP – 1-aminopyrene 
APE1 – Apurinic/apyrimidinic endonuclease 1 
B[a]P – Benzo[a]pyrene 
BER – Base excision repair 
bp – Base pair 
ChIP – Chromatin immunoprecipitation 
CPD – Cyclobutane pyrimidine dimer 
CS – Cockayne syndrome 
CSA – Cockayne syndrome protein A 
CSB – Cockayne syndrome protein B 
C-terminus – Carboxy-terminus of a protein 
D – Diffusion coefficient 
Dlim – Theoretical limit to the diffusion coefficient 
DBD – DNA-binding domain 
DNA – Deoxyribonucleic acid 
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dG-C8-AAF – N-(2’-deoxyguanosin-8-yl)-2-acetylaminofluorene 
dsDNA – Double-stranded DNA 
ELISA – Enzyme-linked immunosorbent assay 
EMSA – Electrophoretic mobility shift assay 
FITC – Fluorescein isothiocyanate 
FL – Fluorescein 
FRET – Fluorescence resonance energy transfer 
GG NER – Global genome nucleotide excision repair 
HMGB1 – High mobility group protein B1 
IDT – Immobilized DNA template 
IF – Immunofluorescence 
IPTG – Isopropyl-β-D-thiogalactoside 
kBT – Thermal energy term, product of Boltzmann constant and temperature 
KD – Equilibrium dissociation constant 
MALS – Multiple angle light scattering 
MM – DNA mismatch 
MMC – Mitomycin C 
MSD – Mean squared displacement 
ND – Non-damaged 
NER – Nucleotide excision repair 
nt – Nucleotide 
N-terminus – Amino-terminus of a protein 
PCNA – Proliferating cell nuclear antigen 
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Polβ – DNA polymerase β 
Qdot – Quantum dot 
RFC – Replication factor C 
RPA – Replication protein A 
SEC – Size exclusion chromatography 
SPR – Surface plasmon resonance 
ssDNA – Single-stranded DNA 
TC NER – Transcription-coupled nucleotide excision repair 
TIRF – Total internal reflection fluorescence 
TFIIH – Transcription factor IIH 
TTD – Trichothiodystrophy 
TTDA – Trichothiodystrophy group A protein, also called p8 
UV – Ultraviolet 
UV-DDB – UV-damaged DNA binding protein 
XAB1 – XPA binding protein 1 
XAB2 – XPA binding protein 2 
XL – Crosslink 
XP – Xeroderma pigmentosum 
XP-A – Xeroderma pigmentosum, complementation group A 
XPA – DNA repair protein complementing XP-A cells 
ZF – Zinc finger 
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Appendix B XPA-DNA Interactions 
Table 1. Published XPA-DNA interactions. 
Unless otherwise noted: studies were performed using full-length wild-type human protein (recombinant, purified), fold specificities are reported as 
overall binding between substrates, and DNA substrates were prepared using short oligonucleotides (less than 60 bp or nt). 
Paper Substrate KD Specificity Method 
Robins et 
al, 1991.93 
UV-irradiated dsDNA (9 kJ/m2)   ~1,000-fold specificitya for UV damage 
over non-damaged dsDNA. Fluence-
dependent affinity for UV damage. 












UV-irradiated dsDNA (6 kJ/m2) 333 nM ~300-fold specificitya for 6-4PP over 
dsDNA. ~4-fold specificity for circular 
ssDNA over circular dsDNA. Higher 
affinity for cisplatin than for non-
damaged dsDNA. No specificity for 
CPD or psoralen adducts. 
EMSAd 
UV-irradiated dsDNA (0-6 kJ/m2),  






Non-damaged dsDNA 1.67 μM 
Non-damaged ssDNA, circular 
 
Non-damaged dsDNA, circular   
89 
Table 1 continued 
Paper Substrate KD Specificity Method 
Asahina et 
al, 1994.79 
UV-irradiated dsDNA (8 kJ/m2)   Specificity for UV-treated DNA over 
non-damaged. Specificity for dsDNA 
over ssDNA. Higher affinity for 
cisplatin than OsO4-treated DNA; 









Non-damaged dsDNA   
Li et al, 
1995.55 
UV-irradiated dsDNA (600 J/m2)   Specificity for UV-treated DNA over 
non-damaged. 
IDTf 
Non-damaged dsDNA   
Kuraoka et 
al, 1996.76 
UV-irradiated dsDNA (8 kJ/m2)   Specificity for UV-treated and cisplatin-









UV-irradiated dsDNA (1 kJ/m2)   Specificity for UV-treated DNA over 
non-damaged. 
Filter binding 
Non-damaged dsDNA   
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Table 1 continued 




AAF-adducted dsDNA   Specificity for AAF and B[a]P over 
non-damaged dsDNA. Specificity for 
C4' pivaloyl adduct within bubble, but 
not in dsDNA. Higher affinity for 3 nt 
mismatch than 1 nt mismatch, 
specificity for both over dsDNA. Lower 
affinity for ssDNA than for dsDNA. 
Higher affinity for 5-nitroindoles than 
for 3-nitropyrroles, specificity for both 






dsDNA with 3 nt MM 
 
dsDNA with 1 nt MM 
 
C4' pivaloyl-adducted dsDNA 
 









Non-damaged dsDNA   
Wakasugi et 
al, 1999.46 
6-4PP-modified dsDNA 6 nM ~70-fold specificitya for UV-treated 
DNA over non-damaged.  
EMSA 
Non-damaged dsDNA 420 nM 
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Table 1 continued 
Paper Substrate KD Specificity Method 
Wang et al, 
2000.97 
6-4PP-modified dsDNA 21 nM ~4.5-fold specificity for ssDNA over 
dsDNA. ~3-fold specificity for 6-4PP. 
~1.3-fold specificity for CPD. 
SPR 
CPD-modified dsDNA 46 nM 
Non-damaged ssDNA 13 nM 
Non-damaged dsDNA 58 nM 
Mustra et 
al, 2001.110 
dsDNA with MMC interstrand XL   ~2-3 fold specificity for MMS crosslink 
over non-damaged dsDNA. 
EMSA 
Non-damaged dsDNA   
Hey et al, 
2001.96 
Cisplatin-adducted dsDNA, 3' FL 415 nM ~3-fold specificity for cisplatin, ssDNA 
loop, mismatched bubble, and ssDNA 
with mixed bases over non-damaged 
dsDNA. ~1.5-fold specificity for 
pyrimidine-rich ssDNA. No 
specificity/worse binding to purine-rich 
ssDNA compared to dsDNA. 
Anisotropy 
dsDNA with 6 nt MM, 3' FL 380 nM 
dsDNA with 3 nt insert on one strand, 3' FL 350 nM 
Non-damaged ssDNA, mixed bases 355 nM 
Non-damaged ssDNA, AG-rich > 3 μM 
Non-damaged ssDNA, TC-rich 786 nM 
Non-damaged dsDNA, 3' FL 1.15 μM 
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Table 1 continued 
Paper Substrate KD Specificity Method 
Missura et 
al, 2001.102 
Cisplatin-adducted dsDNA   Specificity for cisplatin, but not for the 
dinuclear analogue, over non-damaged 
DNA. Specificity for non-hybridized 
substrates as follows: dsDNA insert > 
ssDNA insert > mismatch bubble > 
dsDNA. Specificity for forked 
substrates as follows: 4-way dsDNA > 
3-way dsDNA > Y > non-damaged 
dsDNA. Authors note "extraordinary 
affinity" of XPA for 4-way and 3-way 
dsDNA junctions. Higher affinity for 5-
nitroindoles than for 3-nitropyrroles, 
specificity for both over non-modified 
dsDNA. No affinity for ssDNA. 
EMSA 
Dinuclear cisplatin analogue-adducted 
dsDNA (Pt-Pt) 
 
dsDNA with 3 nt MM 
 
dsDNA with 3 nt insert on one strand 
 
dsDNA with 3 bp insert on one strand 
 
Y shaped DNA 
 
3-way dsDNA junction 
 












dsDNA with 4 nt MM, 5' FL 158 nM ~5-fold lower affinity for mismatch 
compared to dsDNA. 
Stop flowh 
Non-damaged dsDNA, 5' FL 28.9 nM 





Table 1 continued 




6-4PP-modified dsDNA 150 nM ~1.5-fold specificity for 6-4PP over 
non-damaged dsDNA. No specificity 
for CPD. Note: authors report similar 
fold specificity for RPA and XPC on 
same substrates. 
EMSA 
CPD-modified dsDNA 210 nM 
Non-damaged dsDNA 220 nM 
Liu et al, 
2005.90 
AAF-adducted dsDNA, 5' FL 714 nM (KD1), 
55 nM (KD2) 
Note: authors report positive 
cooperativity (Hill = 1.9) 
Anisotropy 
AAF-adducted dsDNA 200 nM Higher affinity for dG-C8-AAF than for 
non-damaged dsDNA. 
EMSA 
Non-damaged dsDNA   
Brabec et al, 
2006.101 
Cisplatin-adducted dsDNA,1,3-GTG   4-5-fold specificity for 1,2-GG adducts, 
when flanked T or A bases, over non-
damaged dsDNA. ~2-fold specificity for 
1,2-GG when flanked by C's. Less than 
2-fold specificity for 1,3-GTG adducts. 
EMSA 
Cisplatin-adducted dsDNA, 1,2-GG 
 




Cisplatin-adducted dsDNA   Specificity for cisplatin over non-
damaged dsDNA. Specificity for forked 
substrates as follows: 4-way dsDNA > 
3-way dsDNA > Y > non-damaged 
dsDNA. 
EMSA 
Y shaped DNA 
 
3-way dsDNA junction 
 
4-way dsDNA junction 
 
Non-damaged dsDNA   
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Table 1 continued 
Paper Substrate KD Specificity Method 
Yang et al, 
2006.100 
Y-shaped DNA 49 nM   Anisotropy 
5' overhang 
 
Similar affinity for 3' overhang and 5' 
overhang. Similar affinity for all 
mismatch bubbles, with or without 
lesion. Higher affinity for bubbles with 
8 or more mismatched bases. Specificity 
for G[8,5-Me]T crosslink over non-
damaged DNA. No specificity for 
intrastrand crosslinks formed by carbon 
tethers. No affinity for non-damaged 






dsDNA with 6 nt MM 
 
AF-adducted DNA, lesion in 6 nt MM 
 
AAF-adducted DNA, lesion in 6 nt MM 
 
AP-adducted DNA, lesion in 6 nt MM 
 
6-4PP-modified DNA, lesion in 6 nt MM 
 
dsDNA with 3, 4, 5, 8, 10, or 12 nt MM 
 
G[8,5-Me]T XLed dsDNA 
 
dsDNA with two-carbon tether XL at GG 
 
dsDNA with three-carbon tether XL at GG 
 




Non-damaged dsDNA   
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Table 1 continued 
Paper Substrate KD Specificity Method 
Mustra et 
al, 2007.91 
dsDNA with MMC interstrand XL   ~2-fold specificity for MMC XL over 
non-damaged DNA. 
EMSA 




FL-dUMP-adducted dsDNA   Specificity for Flu-dUMP over non-
damaged dsDNA 
EMSA 
Brown et al, 
2010.99 
AAF-adducted dsDNA 44 nM Similar affinity for AAF and thymine 
glycol. Specificity for both over non-
damaged dsDNA. 
EMSA 
Thymine glycol-modified dsDNA 48 nM 
Non-damaged dsDNA   
Sugitani et 
al, 2014.77 
Y-shaped DNA, 5' FL (label at dsDNA end) 290 nM ~6-fold specificity for Y-shaped DNA 
over ssDNA and dsDNA. 
Anisotropy 
Non-damaged ssDNA, 5' FL 1.5 μM 
Non-damaged dsDNA, 5' FL 1.7 μM 
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Table 1 continued 
Paper Substrate KD Specificity Method 
Koch et al, 
2015.85 
AAF-adducted dsDNA   Higher affinity for dG-C8-AAF and 
FITC than for cisplatin. 
EMSA 
FITC-adducted dsDNA  
Cisplatin-adducted dsDNA   
AAF-adducted dsDNA 135 nM No specificity for CPD or 6-4PP. EMSAi 
FITC-adducted dsDNA  
Cisplatin-adducted dsDNA  
6-4PP-modified dsDNA  
CPD-modified dsDNA   
Ebert et al, 
2017.86 
AF-adducted dsDNA   Higher affinity for dG-C8-AAF than for 
dG-N2-AAN or dG-C8-AF. Higher 







Non-damaged dsDNA   
Abbreviations, see Appendix A. 
a Specificity calculated to account for nonspecific bases in damaged substrate94  
b XPA fractionated from calf thymus 
c 779 bp and 2961 bp (mixed) DNA 
d Linear DNA substrates, 258 bp; circular substrates, M13 DNA 
e 7250 bp DNA 
f 622 bp and 485 bp (mixed) DNA 
g 2686 bp DNA 
97 
h Xenopus laevis XPA 
i Saccharomyces cerevisiae Rad14 (residues 10-end) 
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Appendix C XPA-Protein Interactions 
Table 2. Published XPA-protein interactions. 
Protein/ 
complex 
Step in NER XPA residues 
involved 





DDB2: 185-226 Interact both on and off DNA. 
Interaction enhances damage binding by 
















XPB: N- and C-







Interact on DNA, and weakly off of 
DNA. XPA forms bridge between XPB, 
XPD, and p52, likely extending to 
p8/TTDA. Interaction not observed by 










Table 2 continued 
Protein/ 
complex 
Step in NER XPA residues 
involved 






Interact both on and off DNA. XPA 
interacts directly with RPA32 and 
RPA70, but not RPA14. KD for RPA 








ERCC1 Incision 67-80 Interact both on and off of DNA. 
Involved in recruitment of XPF/ERCC1 
to DNA. KD for ERCC1 binding to XPA 










PCNA Gap filling 161-170 Connection between NER and replisome. Immunofluorescence53 
FRET53 
ATR n/a 98-219 ATR phosphorylates XPA S196. 





HMGB1 n/a Unknown Interactions may be indirect or dependent 






Table 2 continued  
Protein/ 
complex 
Step in NER XPA residues 
involved 
Notes Methods, Refs. 
PARP1 n/a 213-237 PAR-dependent interaction. Pull-down183 
 
TFIIE n/a Unknown XPA interacts with p34 subunit, but not 
p56-p34 complex. TFIIE does not appear 
to be involved in NER. 
Pull-down118 
XAB1 n/a N-terminus XPA-binding protein 1, GTPase. Yeast two-hybrid184 
XAB2 n/a Unknown XPA-binding protein 2, suggested role in 






Appendix D Studying Protein-DNA Interactions Using Atomic Force Microscopy 
Review of AFM studies on protein-DNA interactions, originally published in Seminars in 
Cell and Developmental Biology. Ref. 129: Beckwitt, E. C., Kong, M. & Van Houten, B. Studying 
















Appendix E Dancing on DNA tightropes: Watching Repair Proteins Interrogate DNA in 
Real Time 
Mini critical review on the uses of the DNA tightrope assay; excerpt from article originally 
published in Microbial Cell. Ref. 135: Klein H. L., Ang K., Arkin M. R., Beckwitt E. C., et al. 
Guidelines for DNA recombination and repair studies: Mechanistic assays of DNA repair 















Appendix F Single-Molecule Methods for Nucleotide Excision Repair: Building a System to 
Watch Repair in Real Time 
Review of and protocols for single molecule methods to study DNA repair proteins, 
originally published in Methods in Enzymology.142 Ref: Kong, M., Beckwitt, E. C., Springall, L., 
Kad, N. M. & Van Houten, B. Single-Molecule Methods for Nucleotide Excision Repair: Building 
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